Podcasts about MSI

Thorin and Yamato preview MSI 2025! They are joined by guests Upset, Zaboutine, Initialise, Keire, and Vestion, who each bring their expertise and perspective on the LoL esports regions they follow. Keep tuning in to Last Free Nation during MSI for more Summoning Insight! Upgrade your wallet today! Get 10% Off Ridge with code SI at https://www.Ridge.com/SI Get the ultimate immersive gaming experience with Turtle Beach today! For a limited time only, head to https://TurtleBeach.com and use Code SUMMONING for 10% off your entire order. Control Body Odor ANYWHERE with Mando and get $5 off off your Starter Pack (that's over 40% off) with promo code SUMMONING at https://www.shopmando.com! Get 50% off FACTOR meals at https://www.factormeals.com/lfn50off with code lfn50off. High-quality, never-frozen meals delivered to your home! The Last Free Nation merch shop is open! Show off your fandom and support us and by purchasing  the high-quality items on our merch shop. Check our website for more info on shipping! https://lastfreenation.shop

The beauty industry often romanticizes the hustle mentality—work harder, work longer, always be on the go. But for many, this can have a real impact on personal relationships, mental health, and overall well-being. In this episode of ASCP Esty Talk, Maggie and Ella dive into the idea of work-life balance and redefine what success looks like in our industry. ASCP Esty Talk with hosts Ella Cressman and Maggie Staszcuk   Produced by Associated Skin Care Professionals (ASCP) for licensed estheticians, ASCP Esty Talk is a weekly podcast, hosted by licensed estheticians, Ella Cressman, ASCP Skin Deep Magazine contributor, and Maggie Staszcuk, ASCP Program Director. We see your passion, innovation, and hard work and are here to support you by providing a platform for networking, advocacy, camaraderie, and education. We aim to inspire you to ask the right questions, find your motivation, and give you the courage to have the professional skin care career you desire.  About Ella Cressman:  Ella Cressman is a licensed esthetician, certified organic formulator, business owner, ingredient junkie, and esthetic cheerleader! As an educator, she enjoys empowering other estheticians and industry professionals to understand skin care from an ingredient standpoint rather than a product-specific view.  In addition to running a skin care practice, Cressman founded a comprehensive consulting group, the HHP Collective, and has consulted for several successful skin care brands.    Connect with Ella Cressman:  Website: www.hhpcollective.com  LinkedIn: linkedin.com/in/ella-cressman-62aa46a    About Maggie Staszcuk:  Maggie Staszcuk serves as the Program Director for ASCP and is the cohost of ASCP Esty Talk podcast. With over 18 years' experience in the esthetics industry, her diverse background includes roles in spa management, spa and med-spa services, and esthetics education. Since becoming a licensed esthetician in 2006, she carries a range of certifications in basic and advanced esthetics. Maggie is dedicated to equipping estheticians with the knowledge and resources they need to thrive in their careers.   Connect with Maggie Staszcuk:  P: 800.789.0411 EXT 1636  E: MStaszcuk@ascpskincare.com    About our Sponsors:   The popular and revolutionary LAMPROBE utilizes radio and high-frequency technology to treat a wide variety of Minor Skin Irregularities™ (MSI)—non-invasively—with instantaneous results. Common conditions treated by the LAMPROBE include: vascular MSI, such as cherry angiomas; dilated capillaries; sebaceous MSI, including cholesterol deposits and milia; and hyperkerantinized MSI, such as keratoses and skin tags.   The LAMPROBE uniquely assists modern, capable, and skilled skin care practitioners to do their work more effectively and with greater client and professional satisfaction. Setting standards in quality, education, and training, the LAMPROBE has become an essential tool enabling skin care practitioners around the world to offer new revenue-enhancing and highly in-demand services.   Website: www.lamprobe.com   Email: info@lamskin.com   Phone: 877-760-2722   Instagram: www.instagram.com/lamprobe   Facebook: www.facebook.com/theLAMPROBE   Skin Script Skin Care provides outstanding products and education, so estheticians prosper and succeed. Skin Script's three pillars are: amazing professional products, excellent customer service that is friendly and fast, and quality education at an approachable price. Skin Script delivers the promise of healthy, vitalized, youthful-looking skin by providing superior, innovative ingredients and formulations that are gentle yet effective. Skin Script Skin Care has been empowering estheticians since 2007 and welcomes you to unite with them in your professional journey.    YouTube: https://www.youtube.com/c/skinscriptrx   Facebook: https://www.facebook.com/skinscriptrx/   Instagram: https://www.instagram.com/skinscriptrx/?hl=en   Massage Envy is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services. Founded in 2002, Massage Envy now has approximately 1,100 franchise locations in 49 states that have together delivered more than 200 million massages and skin care services. Website: www.massageenvy.com/careers/career-areas/esthetician  Facebook: @MassageEnvyCareers LinkedIn: @MassageEnvy   About Associated Skin Care Professionals (ASCP):    Associated Skin Care Professionals (ASCP) is the nation's largest association for skin care professionals and your ONLY all-inclusive source for professional liability insurance, education, community, and career support. For estheticians at every stage of the journey, ASCP is your essential partner. Get in touch with us today if you have any questions or would like to join and become an ASCP member.  Connect with ASCP:  Website: www.ascpskincare.com  Email: getconnected@ascpskincare.com  Phone: 800-789-0411  Facebook: facebook.com/ASCPskincare  Instagram: @ascpskincare   

Welcome back to The Dive Driven by Kia! In this episode, Kobe and Meteos are joined by Emily Rand and Riot Cadmus, Modes Lead, to discuss all the changes coming to ARAM. Then, the crew breaks down Patch 25.13 (the MSI patch) and previews all the teams facing off in Vancouver.Timestamps:0:00 - Intro with Modes Lead Producer Riot Cadmus2:43 - ARAM Changes9:26 - ARAM Champion Buffs13:44 - Brawl, Arena, Swarm, Dominion & Twisted Treeline19:54 - ARAM All Time Teams25:10 - Exhaust in ARAM29:18 - MSI Meta Predictions & Patch 25.13 42:49 - Movistar KOI's Rise to 1st Seed  50:00 - BiliBili Gaming & Anyone's Legend1:01:49 - Gen. G & T11:08:11 - G2 Esports Expectations  1:09:50 - FURIA & GAM Esports 1:31:11 - CTBC Flying Oysters1:18:31 - FlyQuest 

The boys discuss Patch 25.13, Yunara, MSI, EWC, and more on episode 696 of Leaguecast! Email us - mail@leaguecastpodcast.com   Support us - https://www.patreon.com/leaguecast  Tweet us - https://twitter.com/leaguecast   Facebook - https://www.facebook.com/Leaguecast/   Join Our Discord - https://discord.gg/leaguecast  Visit our Website - https://leaguecastpodcast.com/ 

Dr. Shaalan Beg and Dr. Kristen Ciombor discuss practice-changing studies in GI cancers and other novel treatment approaches that were presented at the 2025 ASCO Annual Meeting. Transcript Dr. Shaalan Beg: Hello, I'm Dr. Shaalan Beg, welcoming you to the ASCO Daily News Podcast. I'm a medical oncologist and an adjunct associate professor at UT Southwestern Medical Center in Dallas, Texas. There were some remarkable advances in gastrointestinal cancers that were presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Kristen Ciombor to discuss some exciting GI data. Dr. Ciombor is the Ingram Associate Professor of Cancer Research and a co-leader of Translational Research and the Interventional Oncology Research Program at the Vanderbilt Ingram Cancer Center. Our full disclosures are available in the transcript of this episode. Dr. Ciombor, it's great to have you on the podcast today. Dr. Kristen Ciombor: Thanks, Dr Beg. It's great to be here. Dr. Shaalan Beg: Alright, let's kick it off. Big year for GI cancers. We'll start off with LBA1. This was the ATOMIC study sponsored by NCI and the National Clinical Trials Network (NCTN) and the Alliance group. This is a randomized study of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for stage III mismatch repair deficient colorectal cancer. Dr. Kristen Ciombor: I think this study was really definitely practice-changing, as you can tell because it was a Plenary. But I do have some concerns in terms of how we're actually going to implement this and whether this is the final answer in this disease subtype. So, as you said, the patients were enrolled with stage III resected mismatch repair deficient colon cancer, and then they were randomized to either modified FOLFOX6 with or without atezolizumab. And that's where it starts to become interesting because not many of us give FOLFOX for 6 months like was done in this study. Obviously, the study was done over many years, so that was part of that answer, but also the patients received atezolizumab for a total of 12 months. So the question, I think, that comes from this abstract is, is this practical and is this the final answer? I do think that this is practice-changing, and I will be talking to my patients with resected mismatch repair deficient colon cancer about FOLFOX plus atezolizumab. I think the big question is, do these patients need chemotherapy? And can we do a neoadjuvant approach instead? And that's where we don't have all the answers yet. Dr. Shaalan Beg: Yeah, but it has been great to see immunotherapy make its way into the adjuvant space after having made such a big impact in the metastatic space, but still some unanswered questions in terms of the need for chemotherapy and then the duration of therapy, which I guess we'll have to stay tuned in for the next couple of years to to get a lot of those questions answered. Dr. Kristen Ciombor: Yeah, but a big congratulations to the study team, to the NCTN, the NCI. I mean, this is really a great example of federally funded research that needs to continue. So, great job by the study team. The DFS 10% difference is really very large and certainly a practice-changing study. Dr. Shaalan Beg: Yeah, and and sticking with colon cancer, and and this another federally funded study, but this time funded by a Canadian cancer clinical trials group was LBA3510. This is the CHALLENGE study. It's a randomized phase 3 trial of the impact of a structured exercise program on disease-free survival for stage III or high-risk stage II colon cancer. This study got a lot of buzz, a lot of mainstream press coverage, and a lot of discussions on what that means for us for the patients who we're going to be seeing next week in our clinic. What was your takeaway? Dr. Kristen Ciombor: Yeah, this is a really interesting study, and I was so glad to see it presented because this partially answers one of the questions that patients always have for us in clinic, right? You know, once they've completed their standard chemotherapy and surgery, what else can they do to help prevent recurrence? And so we've always known and sort of extrapolated that healthy lifestyle habits are good, but now we have data, particularly in these patients. Most of them were stage III colon cancer patients, those had high-risk stage II cancer. And basically, the goal was to increase their physical activity by at least 10 MET hours per week. So, my big question, of course, as I came into this presentation was, “Okay, what does that mean exactly? How does that translate to real life?” And really what the author presented and explained was that basically most patients could hit their target by adding a 45- to 60-minute brisk walk 3 to 4 times a week. So I think this is very approachable.  Now, in the confines of the study, this was a structured exercise program, so it wasn't just patients doing this on their own. But I do think kind of extrapolating from that, that this is very achievable for most patients. And not only did this prevent recurrence of their prior cancer, but actually the rate of new primary cancer diagnoses, was less, which is really interesting, especially in the breast and prostate cancer. So this was a really interesting, and I think practice-changing study as well, especially given that this is something that most patients can do. Dr. Shaalan Beg: Yeah, and there was a lot of discussion in the hallways after the presentation in terms of how this really changes our existing practice because most folks already recommend exercise as a way for improving outcomes in cancer patients. So we've already been doing that. Now we have some data on how much it can impact the benefit. But there was some discussion about what the actual degree of impact was. There was a drop-off rate in terms of how long folks were able to stick with this exercise regimen. But you've seen this in clinic when someone have their surgery, they have their chemotherapy, they've been so intimately involved with the oncology world, with the oncology practice, and they somehow feel that they're being let loose into this mean, angry world without any guidance and they're looking for something to do. “What more can I do in terms of my lifestyle?” And then here we have very solid data, as solid as can be for an intervention like exercise, showing that there is an impact and you can give a prescription for exercise when someone wraps up their chemotherapy for colon cancer, thanks to the study. Dr. Kristen Ciombor: Yeah. It was a great study. Dr. Shaalan Beg: Moving to gastroesophageal cancer, another late-breaking abstract. This is LBA5. The MATTERHORN trial was a phase 3 trial of durvalumab plus FLOT for resectable GE junction and gastric cancer. And again, another area where immunotherapy has made an impact, and here we're seeing it move closer for earlier-stage disease. What was your take-home for the MATTERHORN trial? Dr. Kristen Ciombor: Yeah, so this study looked at neoadjuvant perioperative durvalumab plus our current standard chemotherapy of FLOT versus placebo plus FLOT. And this was a large study, almost 1,000 patients were randomized. And the primary endpoint was event-free survival, and it was definitely met in favor of the D + FLOT arm, as Dr. Klempner discussed after Dr Janjigian's presentation. I do think there are still some unanswered questions here. Overall survival is not yet mature, so we do have to wait and see how that shakes out. But it's very interesting and kind of is reflective of what, as you said, we're looking at earlier and earlier lines of therapy, particularly with immunotherapy, in these GI cancer spaces. So it makes a lot of sense to test this and and to look at this. So the toxicity was pretty similar to what we would expect. Primary endpoint was met, but again, we'll have to wait and see what the survival data looks like. Dr. Shaalan Beg: Yeah, and in oncology, we know, especially for treatment that does add additional cost, it does add additional potential toxicity that we want to see that overall survival nudged. I did see some polls on social media asking folks whether their practices changed from this, and I think the results were favoring adding durvalumab for this group of patients but understanding that there are caveats to the addition of treatments and the eventual FDA approval in that indication as well. Dr. Kristen Ciombor: Exactly. I completely agree with that. Dr. Shaalan Beg: All right. How about we stick with gastroesophageal cancer? LBA4002 was trastuzumab deruxtecan versus ramucirumab plus paclitaxel for second-line treatment in HER2-positive unresectable or metastatic gastric cancer or GE junction cancer. This was the DESTINY-Gastric04 study. And again, antibody-drug conjugates making a big impact across different diseases. And here we have more data in the HER2-positive gastric cancer space. Your thoughts on this study? Dr. Kristen Ciombor: Yeah, so this is a really important space in gastroesophageal cancer because the HER2 positivity rate is fairly high as compared to some of our other tumor types. So, I do think one of the important things was that patients did have biopsy confirmation of HER2 status, which was very important, and then they were randomized to either T-DXd versus the kind of second-line standard of ramucirumab-paclitaxel. So this was a great practical study and really answers a question that we had for a while in terms of does anti-HER2 therapy in the second-line really impact and improve survival. So we did see a statistically significant improvement favoring T-DXd. I do think it's always important to look at toxicity, though, too. And there was about almost 14% rate of interstitial lung disease, which of course is the most feared toxicity from some of these antibody-drug conjugates, especially T-DXd. So I do think it's important to keep that in mind, but this is definitely a great addition to the armamentarium for these HER2-positive patients. Dr. Shaalan Beg: And pancreas cancer was on the stage after a very long time with a positive clinical trial. This is Abstract 4006. These were preliminary results from a phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel alone for previously untreated metastatic pancreas cancer. This is a frontline clinical trial of gemcitabine/nab-paclitaxel plus/minus the study drug. There were other cohorts in this study as well, but they reported the results of their part 3B arm. And great to see some activity in the pancreas space. And your thoughts? Dr. Kristen Ciombor: Yeah, we definitely need better treatments in pancreas cancer. This was a very welcome presentation to see. The elraglusib is an inhibitor of GSK-3beta, and it's thought that that mediates drug resistance and EMT. And so this is, I think, a perfect setting to test this drug. So patients basically were randomized. Patients with metastatic pancreas cancer were randomized 2: 1 to gemcitabine/nab-paclitaxel plus or minus this elraglusib. So, what we saw was that overall survival was better with the addition of this new drug. And overall, not only the 1-year overall survival, but also median overall survival.  The thing that was interesting, though, was that we saw that the overall survival rates were 9.3 months with the combination versus 7.2 months with just gemcitabine/nab-paclitaxel. And that's a little bit lower than we've seen in other studies. So, not sure what was going on there. Was it the patients that were a bit sicker? Was it a patient selection, you know, thing? I'm not really sure how to explain that so much. Also, the toxicity profile was much higher in terms of visual impairment, with over 60% of patients being treated with the combination versus 9% with gemcitabine/nab-paclitaxel. So these were mild, grade 1 and 2, but still something to be cautious about. Dr. Shaalan Beg: And especially with this being a phase 2 trial, making sure that in a larger study we're able to better evaluate the toxicity and see if the control arm in the larger confirmatory study performs differently will be really important before this compound makes it to the clinic in our space. But very exciting to see these kinds of results for pancreas adenocarcinoma. Dr. Kristen Ciombor: Yeah. Dr. Shaalan Beg: We've talked, it seems, a couple of times on this podcast about the BREAKWATER clinical trial. We did hear PFS and updated OS data, updated overall survival data on first-line encorafenib plus cetuximab plus modified FOLFOX6 for BRAF-mutated colorectal cancer. This was LBA3500. And eagerly anticipated results – we have all previously heard the progression-free survival results – but here we heard updated overall survival results, and very well-received study it seemed from the audience that time. So what are your takeaways on the updated results for BREAKWATER? Dr. Kristen Ciombor: In my opinion, this was one of the most practice-confirming studies. As you mentioned, we've already seen some of the preliminary data of BREAKWATER at prior meetings. But really what was particularly impactful for me was the median overall survival with the BREAKWATER regimen. So, again, patients received FOLFOX, encorafenib cetuximab in the first line if they had BRAF-mutated V600E-mutated colorectal cancer. And the median PFS was 12.8 months, which was actually really remarkable in this traditionally very aggressive, poor prognosis subtype of tumors. So, by seeing a median overall survival of 30.3 months was just incredible, in my opinion. Just a few years ago, that was considered the median overall survival for all comers for metastatic colorectal cancer. And we know the median overall survival was more in the less than 12 months range for BRAF. So this was incredibly impactful, and I think should be absolutely practice-changing for anyone who is eligible for this regimen.  I think again, where the practice meets the study is what's kind of important to think about too, how long did patients get FOLFOX, and certainly it adds toxicity to add a BRAF-targeted regimen on top of FOLFOX already. So, one of the other interesting things about the study, though, was that even though it didn't complete treatment, they actually did look at encorafenib/cetuximab alone and in the first line without chemotherapy. And those preliminary results actually looked okay, especially for patients who might not be able to tolerate chemotherapy, which we certainly see in practice. So, overall, definitely more data. And I agree that it's certainly practice-changing. Dr. Shaalan Beg: And it completely, as you mentioned, changes the outlook for a person who's diagnosed with BRAF-mutated metastatic colon cancer today versus even 7 or 8 years ago. Dr. Kristen Ciombor: And we're seeing this over and over in other subtypes too, but how you choose to treat the patient up front really matters. So really giving the right regimen up front is the key here. Dr. Shaalan Beg: And along the same lines, Abstract 3501 wanted to answer the question on whether people with MSI-high metastatic colorectal cancer need double checkpoint inhibitor therapy or is single therapy enough. So this [CheckMate-8HW] study compared nivo plus ipi with nivo alone, nivo monotherapy for MSI-high metastatic colorectal cancer. And we've known that both of these are fairly active regimens, but we also know the chance of immune-related adverse events is significantly higher with combination therapy. So this was a much-needed study for this group of patients. And what were your takeaways here? Dr. Kristen Ciombor: This, of course, has been really nivo-ipi in the first-line MSI-high metastatic colorectal cancer is now a standard of care. And not everybody is eligible for it, and there could be reasons, toxicity reasons, and other things too. But as we've been seeing for the last couple of years, immunotherapy clearly beats chemo in this space. And now looking at doublet versus single immunotherapy treatment in the first line, I think really nivo-ipi does beat out monotherapy. I will say, however, there is a caveat in that we still haven't seen the nivo-ipi versus nivo in the first line. So what has been presented thus far has been across all lines of therapy, and that does muddy the waters a little bit. So definitely looking forward and and we've asked this many times and based on the statistical plan and and what not, you know, we just haven't seen that data yet. But I do think it's becoming increasingly important to consider doublet immunotherapy for these patients as long as there are no contraindications. With the again, with the caveat that we have to have these toxicity discussions in the clinic with patients because many patients can tolerate it, you know, this regimen fairly well, but there can be very severe toxicities. So, I think an informed discussion should really be had with each patient before moving forward. Dr. Shaalan Beg: Yeah, informed decision, making them aware of the potential of real significant toxicities, immune-related toxicities with double therapy. But I am curious in your practice, how often do you see people choosing doublet therapy as frontline? Dr. Kristen Ciombor: So patients are really savvy, and a lot of times they've heard this data before or have come across it in patient advocacy groups and other things, and it's really nice to be able to have that conversation of the risk versus benefit. So I will say not all of my patients choose doublet, and many of them are still cured with immunotherapy monotherapy. So the big question there is, will we ever understand who actually needs the doublet versus who can still be cured or have very good long-term outcomes with just the single agent? And that has not been answered yet. Dr. Shaalan Beg: What a great point. So the last abstract I was hoping we could talk about is POD1UM-303 or the INTERAACT2 subgroup analysis and impact of delayed retifanlimab treatment for patients with squamous cell carcinoma of the anal canal. What were your thoughts here? Dr. Kristen Ciombor: This was a study, actually we saw at ESMO, we saw the primary data at ESMO last year, and this was an update with some exploratory analyses. But this was really an important study because once again, we're looking at immunotherapy in later lines of therapy. That's how we started looking at and investigating immunotherapy, and now we're moving it up and up in the treatment course. So this was a study of carboplatin/paclitaxel plus or minus retifanlimab. Actually it was retifanlimab versus placebo. And it was a positive study, as we heard last year. This actually led to FDA approval of this regimen last month, just before ASCO, and it has now been incorporated in the NCCN guidelines as the preferred first-line option.  So what I thought was important from the additional data presented at ASCO was looking at the different subgroups, it did not appear that patients with liver mets or not had different outcomes. So that was really good to see because sometimes in colon cancer we see that immunotherapy doesn't work as well when patients have liver mets. And interestingly, because we use immunotherapy in anal cancer without any biomarkers, unlike with colon cancer or some of the other tumor types, also the authors looked at PD-L1 status, and it did look like maybe patients did a little bit better if they had higher PD-L1 expression, but patients still could benefit even if they were PD-L1 negative. So that was important, I think, and we will continue to see further data come out from this study. I want to mention also that EA2176 just completed accrual, so that was carbo-taxol plus or minus nivolumab. And so we should be seeing that data sometime soon, which will hopefully also confirm the ongoing role for immunotherapy in the first-line setting for anal cancer. Dr. Shaalan Beg: That was a fantastic review. Thank you, Dr Ciombor. Thanks for sharing your valuable insights with us today on the ASCO Daily News Podcast. Dr. Kristen Ciombor: Thanks for having me here. Dr. Shaalan Beg: And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode. And if you value the insights that you hear on the podcast, please take a moment to rate, review, and subscribe, wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Shaalan Beg  @ShaalanBeg  Dr. Kristen Ciombor @KristenCiombor Follow ASCO on social media:    @ASCO on Twitter   @ASCO on BlueSky  ASCO on Facebook    ASCO on LinkedIn    Disclosures:   Dr. Shaalan Beg:   Consulting or Advisory Role: Ipsen, Cancer Commons, Foundation Medicine, Science37, Nant Health, Lindus Health Speakers' Bureau: Sirtex Research Funding (Inst.): Delfi Diagnostics, Universal Diagnostics, Freenome Dr. Kristen Ciombor: Consulting or Advisory Role: Pfizer, Incyte, Exelixis, Bayer, ALX Oncology, Tempus, Agenus, Taiho Oncology, Merck, BeiGene Research Funding (Inst.): Pfizer, Boston Biomedical, MedImmune, Onyx, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Incyte, Amgen, Sanofi, Bristol-Myers Squibb, Array BioPharma, Incyte, Daiichi Sankyo, Nucana, Abbvie, Merck, Pfizer/Calthera, Genentech, Seagen, Syndax Travel, Accommodations, Expenses: Incyte, Tempus

Send us a textWe dive into the major gaming announcements from PlayStation's State of Play and Xbox's Showcase events, comparing the different strategies each platform is taking and highlighting the most exciting upcoming games and hardware.• PlayStation VR is making a comeback with the upcoming game "Thief" featuring a new protagonist• Mortal Kombat Legacy Collection includes 20 games spanning multiple platforms for $69.99• Metal Gear Solid: Snake Eater remaster and Astro Bot DLC announcements generated significant excitement• PlayStation revealed their first official fight stick with wireless capabilities and mechanical switches• Xbox partnered with ASUS ROG and MSI to create Windows-powered gaming handhelds estimated to cost $600-800• Gears of War Reloaded and other Xbox games will come to PlayStation with physical releases while remaining digital-only on Xbox• Final Fantasy games are finally coming to Xbox but with disappointing early sales figures• Clockwork Revolution emerged as the standout game from the Xbox showcase• The "Megan 2" movie trailer shows a shift from horror to more sci-fi action• Gaming is increasingly incorporating political themes, raising questions about appropriate boundaries

Esportmaníacos 2310: En el programa de hoy hemos seguido haciendo un poco de repaso del MSI, analizando al máximo favorito, Gen G. También hemos hablado de Los Ratones llegando a la final del EMEA Master (otra vez) y qué dice esto de los equipos de ERL. Finalmente, hemos hecho la tierlist de junglas del MSI. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos ¡Nuestro canal de VODs!: youtube.com/⁨@Esportmaniacosvods⁩ 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro 00:17:00 - Los Ratones a la final del EMEA 00:37:20 - El mercato de LEC 00:58:20 - Bwipo quiere a Myrwn para el MSI 01:03:58 - ¡Llega el Game Changers a LoL! 01:15:00 - Falta de talento en la retransmisión internacional 01:32:20 - Analizamos a Gen G 01:45:00 - Tierlist de junglas

In a new Summoning Insight, Thorin and Yamato discuss the banger LTA North Final between FlyQuest and Cloud9, Chovy taking GenG through another strong LCK split, whether AL can bring the LPL a win at MSI, and more! Get the ultimate immersive gaming experience with Turtle Beach today! For a limited time only, head to https://TurtleBeach.com and use Code SUMMONING for 10% off your entire order. ​Upgrade your wallet today! Get 10% Off Ridge with code SI at https://www.Ridge.com/SI Control Body Odor ANYWHERE with Mando and get $5 off off your Starter Pack (that's over 40% off) with promo code SUMMONING at https://www.shopmando.com! Go to https://www.buyraycon.com/lfn TODAY to get up to 15% off their best-selling Everyday Earbuds! 

In this episode of ASCP Esty Talk, Ella and Maggie dive into the wilder side of off-label skin care—the hacks your clients swear by (and you secretly hope they don't try). From using Monistat as makeup primer to dabbing toothpaste on zits and slathering on milk of magnesia to control shine, we unpack the surprising science, hidden risks, and when to gently intervene. Whether these creative shortcuts are rooted in desperation, TikTok trends, or passed-down “wisdom,” we're separating the myths from the mildly effective. Spoiler alert: Not all hacks belong in your routine, but some may spark a safer, pro-grade alternative. Read the Skin Deep article here ASCP Esty Talk with hosts Ella Cressman and Maggie Staszcuk   Produced by Associated Skin Care Professionals (ASCP) for licensed estheticians, ASCP Esty Talk is a weekly podcast, hosted by licensed estheticians, Ella Cressman, ASCP Skin Deep Magazine contributor, and Maggie Staszcuk, ASCP Program Director. We see your passion, innovation, and hard work and are here to support you by providing a platform for networking, advocacy, camaraderie, and education. We aim to inspire you to ask the right questions, find your motivation, and give you the courage to have the professional skin care career you desire.  About Ella Cressman:  Ella Cressman is a licensed esthetician, certified organic formulator, business owner, ingredient junkie, and esthetic cheerleader! As an educator, she enjoys empowering other estheticians and industry professionals to understand skin care from an ingredient standpoint rather than a product-specific view.  In addition to running a skin care practice, Cressman founded a comprehensive consulting group, the HHP Collective, and has consulted for several successful skin care brands.    Connect with Ella Cressman:  Website: www.hhpcollective.com  LinkedIn: linkedin.com/in/ella-cressman-62aa46a    About Maggie Staszcuk:  Maggie Staszcuk serves as the Program Director for ASCP and is the cohost of ASCP Esty Talk podcast. With over 18 years' experience in the esthetics industry, her diverse background includes roles in spa management, spa and med-spa services, and esthetics education. Since becoming a licensed esthetician in 2006, she carries a range of certifications in basic and advanced esthetics. Maggie is dedicated to equipping estheticians with the knowledge and resources they need to thrive in their careers.   Connect with Maggie Staszcuk:  P: 800.789.0411 EXT 1636  E: MStaszcuk@ascpskincare.com    About our Sponsors:   The popular and revolutionary LAMPROBE utilizes radio and high-frequency technology to treat a wide variety of Minor Skin Irregularities™ (MSI)—non-invasively—with instantaneous results. Common conditions treated by the LAMPROBE include: vascular MSI, such as cherry angiomas; dilated capillaries; sebaceous MSI, including cholesterol deposits and milia; and hyperkerantinized MSI, such as keratoses and skin tags.   The LAMPROBE uniquely assists modern, capable, and skilled skin care practitioners to do their work more effectively and with greater client and professional satisfaction. Setting standards in quality, education, and training, the LAMPROBE has become an essential tool enabling skin care practitioners around the world to offer new revenue-enhancing and highly in-demand services.   Website: www.lamprobe.com   Email: info@lamskin.com   Phone: 877-760-2722   Instagram: www.instagram.com/lamprobe   Facebook: www.facebook.com/theLAMPROBE   Skin Script Skin Care provides outstanding products and education, so estheticians prosper and succeed. Skin Script's three pillars are: amazing professional products, excellent customer service that is friendly and fast, and quality education at an approachable price. Skin Script delivers the promise of healthy, vitalized, youthful-looking skin by providing superior, innovative ingredients and formulations that are gentle yet effective. Skin Script Skin Care has been empowering estheticians since 2007 and welcomes you to unite with them in your professional journey.    YouTube: https://www.youtube.com/c/skinscriptrx   Facebook: https://www.facebook.com/skinscriptrx/   Instagram: https://www.instagram.com/skinscriptrx/?hl=en   Massage Envy is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services. Founded in 2002, Massage Envy now has approximately 1,100 franchise locations in 49 states that have together delivered more than 200 million massages and skin care services. Website: www.massageenvy.com/careers/career-areas/esthetician  Facebook: @MassageEnvyCareers LinkedIn: @MassageEnvy   About Associated Skin Care Professionals (ASCP):    Associated Skin Care Professionals (ASCP) is the nation's largest association for skin care professionals and your ONLY all-inclusive source for professional liability insurance, education, community, and career support. For estheticians at every stage of the journey, ASCP is your essential partner. Get in touch with us today if you have any questions or would like to join and become an ASCP member.  Connect with ASCP:  Website: www.ascpskincare.com  Email: getconnected@ascpskincare.com  Phone: 800-789-0411  Facebook: facebook.com/ASCPskincare  Instagram: @ascpskincare   

Aidan & Colton discuss Patch 25.12, Arena's return, Aram's update, MSI, and more on episode 695 of Leaguecast! Email us - mail@leaguecastpodcast.com   Support us - https://www.patreon.com/leaguecast  Tweet us - https://twitter.com/leaguecast   Facebook - https://www.facebook.com/Leaguecast/   Join Our Discord - https://discord.gg/leaguecast  Visit our Website - https://leaguecastpodcast.com/ 

Take a look at NZXT! - https://nzxt.co/travis ( Use code: travis5 )Check out Enchanted Travel at enchantedtravel.com !Follow Travis on Twitch: http://twitch.tv/travisgaffordSupport: https://linktr.ee/tgisupport00:00:00 Intro 00:14:14 Buttercup predicts FLY will have at minimum a semifinals appearance at MSI00:24:33 Tpepper's take: With recent performances at the last few worlds, LEC 2nd seed and LTA North 2nd seed should compete at MSI for the spot.00:39:42 mlewisno's take: part of why the LTA is exciting is because both C9 and FlyQuest have their villainous and heroic sides00:57:11 Frankalin asks Massu about his efforts in building his story and brand through content01:10:28 Enchanted Travel break!01:18:18 jarglyparf's take: Srtty being benched is the worst thing that DIG could've done01:32:12 kakashi's take: even though C9 lost to FLY, the narrative dominance of FLY is overblown01:44:40 Disappointment around MSI01:51:00 NZXT break! 01:53:10 ProfX's take: Near Airport leaving is a waste of the slot02:04:50 Outro

BUFFALO, NY - June 17, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on June 10, 2025, titled “Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence.” The study, led by first author Kavin Sugumar and corresponding author Jordan M. Winter, from University Hospitals Seidman Cancer Center, reports on a rare group of pancreatic cancer (PC) patients who responded remarkably well to immunotherapy, a treatment typically considered ineffective for this cancer type. The analysis, which includes data from 14 patients across multiple U.S. institutions, identifies outcomes that could help refine treatment strategies for one of the most aggressive and deadly forms of cancer. “Between 2020–21, 471 oncologists from 91 major cancer centers in the United States were contacted.” Pancreatic cancer has among the lowest survival rates and few effective therapies. While immunotherapy has transformed the treatment landscape for several other cancers, it generally offers little benefit for pancreatic cancer. However, this study highlights a small but important group of patients who experienced significant and sustained responses to immune-based treatment without chemotherapy. Most had advanced or metastatic disease and had already progressed after standard treatments. Among the 14 patients, 82% had partial tumor shrinkage, and nearly one-third had a notable decrease in tumor markers. The median progression-free survival was 12 months, and most patients were still alive at follow-up, with survival rates of 80% at one year and 70% at two years. These outcomes contrast sharply with standard therapies, which often provide only a few months of benefit for similar patients. Interestingly, while some patients had high microsatellite instability (MSI-high)—a known marker for immunotherapy success—more than half did not, suggesting other biological mechanisms may be involved. This result highlights the need for new biomarkers to be discovered to predict treatment response in future studies. This case series is the largest focused exclusively on exceptional immunotherapy responders in pancreatic cancer. By excluding patients who received chemotherapy, the study isolates the effects of immune-based drugs, including PD-1 inhibitors such as pembrolizumab and nivolumab, CTLA-4 inhibitors like ipilimumab, and agents targeting macrophages. While the sample size is small, the findings challenge the assumption that immunotherapy is ineffective for nearly all pancreatic cancer patients. The study suggests that, under certain biological conditions, this treatment can be remarkably successful. Further research is needed to understand the underlying mechanisms. This work supports the need to reconsider how clinical trials are designed for pancreatic cancer and who is eligible for immunotherapy. Broader criteria and more personalized molecular profiling could help uncover hidden opportunities for treatment in this highly lethal cancer. DOI - https://doi.org/10.18632/oncotarget.28739 Correspondence to - Jordan M. Winter - jordan.winter@UHHospitals.org Video short - https://www.youtube.com/watch?v=VeWTcuVmqgM Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28739 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Esportmaníacos 2308: En el programa de hoy hemos analizado un poco de mercato de LEC con todas las novedades que trajo Eros en Al Lío Podcast. Después hemos tocado varios temas relativos al MSI: ¿qué tal viene T1?, ¿por qué han caído los clasificados al FST?. Después hemos terminado con nuestra TIERLIST DE TOP LANERS. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos ¡Nuestro canal de VODs!: youtube.com/⁨@Esportmaniacosvods⁩ 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro + EMEA Master 00:16:40 - Mercato de LEC 01:15:47 - Analizamos a las Ostras 01:22:20 - ¿Por qué los del FST no han llegado al MSI? 01:32:53 - ¿Cómo llega T1 al MSI? 01:45:26 - Tierlist de top laners

Welcome back to a spicy episode of The Dive Driven by Kia. The crew take on the bet payoffs they made earlier in the season featuring some extremely spicy peppers while recapping the LTA North Split 2 Conference Finals. After some time to cool off, we look ahead to MSI with the teams that have qualified, and talk region competitiveness and roster changes.Timestamps:0:00 Intro and the Spicy Pepper Bet5:20 C9 vs FLY Finals Recap 9:29 Zven Post Game Interview 12:35 C9 Nerves19:24 Game 323:04 Region competitiveness25:07 MSI & Scrims33:06 Roster Changes: Umti41:30 Other Roster Changes47:22 Back from break!47:25 MSI Attendees54:33 Outro

Esportmaníacos 2307: En el programa de hoy hemos charlado largo y tendido sobre el MSI, los equipos que asistirán al evento y cómo funcionará el segundo torneo internacional del año. Al final hemos tocado un poco de Mercato para analizar los movimientos de la LEC en este momento entre seasons. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos ¡Nuestro canal de VODs!: youtube.com/⁨@Esportmaniacosvods⁩ 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro y hablamos de NA 00:16:50 - Filtraciones de la nueva campeona 00:33:45 - TODO sobre el MSI 00:57:17 - El play in del MSI 01:23:24 - ¿Europa puede quedar Top 2? 01:37:20 - ¿Cuántas partidas ha jugado cada equipo del MSI? 01:45:15 - ¡MERCATO DE LEC!

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.Het weekend staat voor de deur. Wel ietsje minder warm dan de afgelopen dagen. Want wat is het heet in de studio tijdens de opnames van de nieuwe editie van Einde van de Week Live. Drie hosts werken zich in het zweet om samen met de community al het game-gerelateerde nieuws van de afgelopen week door te nemen. Achter de desk zitten dit keer JJ, Koos & Skate. Zij gaan het hebben over onder andere de eerste speelsessies met Resident Evil Requiem, 48 jaar Capcom, het succes van de Switch 2 en de verwikkelingen rondom de launch van MindsEye. Dit alles en vele andere topics komen voorbij in de Einde van de Week Live van vrijdag 13 mei 2025.Resident Evil Requiem doet de boel flink opschrikkenNaast het vele gamenieuws hebben de drie ook nog een portie Cool of Serious Uncool voor jullie in petto. Te samen levert dit een volle show op die vooral positief en leuk nieuws bevat. Met andere woorden, een heerlijk begin van het weekend.Profiteer van fijne kortingen en maak kans op 250 cadeaukaart bij de ‘Upgrade Jouw Zomer' actie van BOL en MSIDe ‘E3'-periode is een speciale tijd. Een waar zomers spektakel voor gamers. En dus dachten MSI en Bol, hoe kunnen we deze mensen extra blij maken? De uitkomst is de ‘Upgrade Jouw Zomer actie'. Wat houdt de actie in? Heel simpel. Bij de aankoop van een MSI laptop met een RTX 4070 videokaart of hoger aan boord (en ja, de 50-serie hoort daar ook bij), pak jij fijne kortingen EN je maakt kans op een zomerse Bol.com cadeaukaart ter waarde van 250 euro. Kun je mooi een nieuwe zwembroek, een koelbox of parasol kopen. De actie is hier te vinden. Have fun: https://msi.gm/S67F9AF0.Krijg maar liefst 40% exclusieve korting bij aanschaf Philips Hue PC Gradient LightstripPhilips Hue heeft een mooie, exclusieve aanbieding voor jou klaar staan. Het betreft de eersteklas Gradiant LED-strips die elke ruimte verlichten. Je kunt ze net als Boris, Daan en Koos achter je scherm of monitor verwerken en ze kleuren mee op de vibe van de game of film. Interesse? Pak hier exclusief 40% korting op jouw PC Gradient Lightstrip: https://ap.lc/BDDgR . Vul daarvoor de code 'Gamekings40' in bij het afrekenen. Ja toch...     Check het concert van Nine Inch Nails op 29 mei in de Ziggo DomeOp 29 juni aanstaande kun je in de Ziggo Dome in Amsterdam het concert van de brute en door Jelle, Steven en JJ gewaardeerde band Nine Inch Nails bijwonen. De muziek van de groep van frontman Trent Reznor, zal veel gamers bekend in de oren klinken, want het zit in meer dan 20 videogames. Van de Call of Duty - en Batman franchise tot Doom en Dead Island, de beukende sound van deze band heerst er. Check hun tracks hier maar eens. Wil je bij dit concert aanwezig zijn, dan kun je hier de kaarten scoren: https://www.mojo.nl/concerten/nine-inch-nails .Timestamps:00:00:00 Intro00:02:00 Huishoudelijke mededeling: MSI00:06:45 MindsEye review, betaalde stream afgebroken 00:12:24 PlayStation lineup 00:18:51 Metal Gear Online wordt Fux Hunt 00:20:38 The Witcher 3 komt met nieuwe DLC in 202600:24:43 Bloober Team bezig met Silent Hill remake00:26:01 We weten wat meer over Resident Evil Requiem00:30:24 Nintendo Nederland cliamt niet snelst verkopende console aller 00:35:41 Total War reeks bestaat 25 jaar00:38:34 Oktober vol met toffe games 00:41:30 BULLETTIME00:44:00 2026 ook niet slecht 00:48:01 Sonic Crossroads is een contender voor de mensen die Mario Kart World minder leuk vonden 00:50:54 The Expanse: Osiris Reborn 00:54:44 Stellar Blade PC record aantallen 00:56:45 Red Dead Redemption II next gen update 00:58:51 Capcom 48 jaar geleden opgericht 01:02:16 Wie te kiezen bij Mario Karty World 01:03:55 Elden Ring eindbaas01:08:00 BULLETTIME 01:12:00 COOL SERIOUS UNCOOL

Esportmaníacos 2306: En el programa de hoy hemos hablado del podcast oficial de la LEC y la forma en la que han tratado a Movistar KOI después de ganar el split de primavera. Por otro lado, hemos tocado la noticia de NAVI entrando en la LEC, ya que se ha hecho oficial y hemos visto a los equipos clasificados al MSI de China y Corea. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos ¡Nuestro canal de VODs!: youtube.com/⁨@Esportmaniacosvods⁩ 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro 00:14:10 - ¿La LEC contra KOI? 01:08:30 - NAVI a la LEC 01:34:40 - GEN G y BLG al MSI

Esportmaníacos 2305 - En el programa de hoy hemos hablado de KOI y G2 y la posibilidad de que la LEC sea la 2ª mejor región del mundo. También del polémico nuevo patrocinador de Sheep Esports y de lo que opina Mikyx sobre Fnatic y G2. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 Intro 00:14:30 Mfreak nos habla de LCK: GENG vs HLE 00:32:38 Sheep Esports anuncia Patrocinador de Poker/Apuestas 01:08:25 Clasificados a MSI, Expectativas del evento 01:33:00 Audiencias LEC de mano de Esports Charts 01:51:05 MikyX habla sobre Tiempo Libre en G2 vs en FNC

Is it actually safe to perform chemical peels during the summer months? In this episode of ASCP Esty Talk, Maggie and Ella tackle one of the hottest debated topics in esthetics, covering concerns like UV damage and post-inflammatory hyperpigmentation, offering tips on client selection and aftercare, and exploring safer summer alternatives. Tune in as they navigate the peel season—no matter the weather. ASCP Esty Talk with hosts Ella Cressman and Maggie Staszcuk   Produced by Associated Skin Care Professionals (ASCP) for licensed estheticians, ASCP Esty Talk is a weekly podcast, hosted by licensed estheticians, Ella Cressman, ASCP Skin Deep Magazine contributor, and Maggie Staszcuk, ASCP Program Director. We see your passion, innovation, and hard work and are here to support you by providing a platform for networking, advocacy, camaraderie, and education. We aim to inspire you to ask the right questions, find your motivation, and give you the courage to have the professional skin care career you desire.  About Ella Cressman:  Ella Cressman is a licensed esthetician, certified organic formulator, business owner, ingredient junkie, and esthetic cheerleader! As an educator, she enjoys empowering other estheticians and industry professionals to understand skin care from an ingredient standpoint rather than a product-specific view.  In addition to running a skin care practice, Cressman founded a comprehensive consulting group, the HHP Collective, and has consulted for several successful skin care brands.    Connect with Ella Cressman:  Website: www.hhpcollective.com  LinkedIn: linkedin.com/in/ella-cressman-62aa46a    About Maggie Staszcuk:  Maggie Staszcuk serves as the Program Director for ASCP and is the cohost of ASCP Esty Talk podcast. With over 18 years' experience in the esthetics industry, her diverse background includes roles in spa management, spa and med-spa services, and esthetics education. Since becoming a licensed esthetician in 2006, she carries a range of certifications in basic and advanced esthetics. Maggie is dedicated to equipping estheticians with the knowledge and resources they need to thrive in their careers.   Connect with Maggie Staszcuk:  P: 800.789.0411 EXT 1636  E: MStaszcuk@ascpskincare.com    About our Sponsors:   The popular and revolutionary LAMPROBE utilizes radio and high-frequency technology to treat a wide variety of Minor Skin Irregularities™ (MSI)—non-invasively—with instantaneous results. Common conditions treated by the LAMPROBE include: vascular MSI, such as cherry angiomas; dilated capillaries; sebaceous MSI, including cholesterol deposits and milia; and hyperkerantinized MSI, such as keratoses and skin tags.   The LAMPROBE uniquely assists modern, capable, and skilled skin care practitioners to do their work more effectively and with greater client and professional satisfaction. Setting standards in quality, education, and training, the LAMPROBE has become an essential tool enabling skin care practitioners around the world to offer new revenue-enhancing and highly in-demand services.   Website: www.lamprobe.com   Email: info@lamskin.com   Phone: 877-760-2722   Instagram: www.instagram.com/lamprobe   Facebook: www.facebook.com/theLAMPROBE   Skin Script Skin Care provides outstanding products and education, so estheticians prosper and succeed. Skin Script's three pillars are: amazing professional products, excellent customer service that is friendly and fast, and quality education at an approachable price. Skin Script delivers the promise of healthy, vitalized, youthful-looking skin by providing superior, innovative ingredients and formulations that are gentle yet effective. Skin Script Skin Care has been empowering estheticians since 2007 and welcomes you to unite with them in your professional journey.    YouTube: https://www.youtube.com/c/skinscriptrx   Facebook: https://www.facebook.com/skinscriptrx/   Instagram: https://www.instagram.com/skinscriptrx/?hl=en   Massage Envy is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services. Founded in 2002, Massage Envy now has approximately 1,100 franchise locations in 49 states that have together delivered more than 200 million massages and skin care services. Website: www.massageenvy.com/careers/career-areas/esthetician  Facebook: @MassageEnvyCareers LinkedIn: @MassageEnvy   About Associated Skin Care Professionals (ASCP):    Associated Skin Care Professionals (ASCP) is the nation's largest association for skin care professionals and your ONLY all-inclusive source for professional liability insurance, education, community, and career support. For estheticians at every stage of the journey, ASCP is your essential partner. Get in touch with us today if you have any questions or would like to join and become an ASCP member.  Connect with ASCP:  Website: www.ascpskincare.com  Email: getconnected@ascpskincare.com  Phone: 800-789-0411  Facebook: facebook.com/ASCPskincare  Instagram: @ascpskincare   

Esportmaníacos 2304: En el programa de hoy hemos tenido a Jandro del Barça Esports hablando del EMEA Masters y de cómo ha funcionado el equipo durante la Superliga Domino's. Por otro lado, también hemos visto qué equipos están cerca del MSI, cómo irá G2 y KOI en el torneo. Finalmente, hemos tocado el mercato de LEC. APÓYANOS AQUÍ https://www.patreon.com/Esportmaniacos https://www.twitch.tv/esportmaniacos ¡Nuestro canal de VODs!: youtube.com/⁨@Esportmaniacosvods⁩ 🔁Nuestras redes🔁 https://twitter.com/Esportmaniacos https://www.tiktok.com/@esportmaniacos 💙Referido de AMAZON: https://amzn.to/36cVx3g 00:00:00 - Intro 00:17:08 - Viene Jandro del Barça Esports 00:59:25 - Expectativas para el MSI 01:25:00 - Viene Sharin 01:39:00 - Mercato de LEC

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.Het weekend is daar. Vlak voor je. Je kunt het bijna aanraken. Wij gaan je over de drempel heen helpen met een extra leuke aflevering van dé talkshow over gaming in Nederland: EvdWL. Het betreft een speciale editie waarin de vrijwel helemaal in het teken staat van de ‘E3'. JJ, Koos en Shelly vieren nog even de launch van de Switch 2, ze kijken terug op State of Play die PlayStation woensdag gaf en ze kijken vooruit naar de aankomende Summer Game Fest en de Xbox Showcase. Dit alles en nog veel, veel meer kun consumeren in de Einde van de Week Live van vrijdag 6 juni 2025.Hadden we echte een hardware launchday gevoel bij de launch van de Switch 2?Wat gaan we de komende 72 uur allemaal meemaken? Welke nieuwe games worden aangekondigd die we nog niet kenden? Of is het vooral nieuwe beeld van titels die al bekend zijn en de komende 365 dagen gaan uitkomen? In deze episode van EvdWL gaan we ons alvast verheugen op en toewerken naar de Summer Game Fest stream van vanavond 22:30 uur en de Xbox Showcase stream van zondag 18:30 uur.Profiteer van fijne kortingen en maak kans op 250 cadeaukaart bij de 'Upgrade Jouw Zomer' actie van BOL en MSIDe ‘E3'-periode is een speciale tijd. Een waar zomers spektakel voor gamers. En dus dachten MSI en Bol, hoe kunnen we deze mensen extra blij maken? De uitkomst is de ‘Upgrade Jouw Zomer actie'. Wat houdt de actie in? Heel simpel. Bij de aankoop van een MSI laptop met een RTX 4070 videokaart of hoger aan boord (en ja, de 50-serie hoort daar ook bij), pak jij fijne kortingen EN je maakt kans op een zomerse Bol.com cadeaukaart ter waarde van 250 euro. Kun je mooi een nieuwe zwembroek, een koelbox of parasol kopen. De actie is hier te vinden. Have fun. Check de nieuwe, snelle en kleurrijke Rival 3 Gen 2 muizen van SteelSeriesSteelseries is een brand dat zich kan meten met de top als het gaat om peripherals voor PC gamers. Neem nu de Rival 3 Gen 2 muizen van SteelSeries. Scherp geprijsd en met een respons bij 1,35ms de snelste in hun klasse. Info over deze fijne, betaalbare muis (met en zonder draad) en de mogelijkheid tot aanschaf, kun je hier vinden.Scoor de LG CineBeam Q 4K beamer met een dikke kortingLG heeft een buitenkansje voor mensen die van fijne en handzame gear houden. Met de draagbare CineBeam Q 4K beamer kun je jouw films en series bekijken waar je maar wil. In knisperend strak beeld. De CineBeam Q bevat 8,3 megapixels en tovert een scherm tot 120 inch op je muur of plafond. En ja, je kunt er ook een console op aansluiten. Er geldt nu hier een aanbieding bij LG die je 100 euro korting + een 60 euro voucher voor Pathé geeft bij aanschaf.Timestamps:00:00:00 Einde van de Week Live van 6 juni00:03:43 Huishoudelijke mededeling: MSI00:08:52 Eerste indrukken van de Switch 2.00:10:33 Koos zijn verhaal00:16:10 Switch 2's stapelen...00:21:05 Coke & Pringles.00:22:11 Cyberpunk 2077 op Switch.00:31:24 Terugkijken op State of Play.00:52:28 BULLETTÎME: SteelSeries00:56:54 Wat verwachten we van de Summer Game Fest vanavond 01:12:10 Wat verwachten we Xbox Showcase?01:22:29 BULLETTÎME: LG 01:24:41 Baldur's Gate 1 en 2 op Game Pass.01:25:48 Cyberpunk 2077 2.3 update.01:26:59 Battlefield 6 tanks.01:31:44 CD Projekt Red heeft gekeken naar Kingdom Come Deliverance 2.01:38:19 Tech Elden Ring Nightreign niet uitmuntend.01:39:54 Tim Sweeney Epic baas over AI en Zelda Breath of the Wild.01:44:43 Succes Forza Horizon 5.01:46:00 Twee grote namen lopen voor launch weg bij studio achter MindsEye.01:48:00 Waar horen de sticks?

Beyond treatments and product recommendations, it's the meaningful moments, consistent care, and personal touches that build trust and long-term loyalty. This week on ASCP Esty Talk, Ella and Maggie dive into one of the most powerful aspects of being an esthetician—creating authentic, emotional connections with clients. ASCP Esty Talk with hosts Ella Cressman and Maggie Staszcuk   Produced by Associated Skin Care Professionals (ASCP) for licensed estheticians, ASCP Esty Talk is a weekly podcast, hosted by licensed estheticians, Ella Cressman, ASCP Skin Deep Magazine contributor, and Maggie Staszcuk, ASCP Program Director. We see your passion, innovation, and hard work and are here to support you by providing a platform for networking, advocacy, camaraderie, and education. We aim to inspire you to ask the right questions, find your motivation, and give you the courage to have the professional skin care career you desire.  About Ella Cressman:  Ella Cressman is a licensed esthetician, certified organic formulator, business owner, ingredient junkie, and esthetic cheerleader! As an educator, she enjoys empowering other estheticians and industry professionals to understand skin care from an ingredient standpoint rather than a product-specific view.  In addition to running a skin care practice, Cressman founded a comprehensive consulting group, the HHP Collective, and has consulted for several successful skin care brands.    Connect with Ella Cressman:  Website: www.hhpcollective.com  LinkedIn: linkedin.com/in/ella-cressman-62aa46a    About Maggie Staszcuk:  Maggie Staszcuk serves as the Program Director for ASCP and is the cohost of ASCP Esty Talk podcast. With over 18 years' experience in the esthetics industry, her diverse background includes roles in spa management, spa and med-spa services, and esthetics education. Since becoming a licensed esthetician in 2006, she carries a range of certifications in basic and advanced esthetics. Maggie is dedicated to equipping estheticians with the knowledge and resources they need to thrive in their careers.   Connect with Maggie Staszcuk:  P: 800.789.0411 EXT 1636  E: MStaszcuk@ascpskincare.com    About our Sponsors:   The popular and revolutionary LAMPROBE utilizes radio and high-frequency technology to treat a wide variety of Minor Skin Irregularities™ (MSI)—non-invasively—with instantaneous results. Common conditions treated by the LAMPROBE include: vascular MSI, such as cherry angiomas; dilated capillaries; sebaceous MSI, including cholesterol deposits and milia; and hyperkerantinized MSI, such as keratoses and skin tags.   The LAMPROBE uniquely assists modern, capable, and skilled skin care practitioners to do their work more effectively and with greater client and professional satisfaction. Setting standards in quality, education, and training, the LAMPROBE has become an essential tool enabling skin care practitioners around the world to offer new revenue-enhancing and highly in-demand services.   Website: www.lamprobe.com   Email: info@lamskin.com   Phone: 877-760-2722   Instagram: www.instagram.com/lamprobe   Facebook: www.facebook.com/theLAMPROBE   TiZO Mineral Sunscreens set the standard for aesthetic elegance with tinted and non-tinted formulas for use on virtually all skin types and tones. Our name reflects our commitment: TIZO = Titanium dioxide + Zinc Oxides. All TiZO products are reef-friendly and 100% free of chemical sunscreens, dyes, fragrances, gluten, phthalates, and parabens.  TiZO Photoceutical Skincare is the perfect partner to our sunscreens in the fight against photoaging. These silky, elegant products address tone, texture and hydration while helping to prevent further damage. From our flagship TiZO3 Primer/Sunscreen SPF 40 to our gentle Ultra Zinc formulations to our NEW Advanced Vitamin C+E Serum with Bakuchiol, TIZO has the ideal selection of products to Protect, Repair, and Revitalize skin.   Website: https://tizoskin.com/  Facebook: @tizoskin  Pinterest: @tizoskin  Instagram: @tizoskin  YouTube: @tizoskin     Massage Envy is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services. Founded in 2002, Massage Envy now has approximately 1,100 franchise locations in 49 states that have together delivered more than 200 million massages and skin care services. Website: www.massageenvy.com/careers/career-areas/esthetician  Facebook: @MassageEnvyCareers LinkedIn: @MassageEnvy   About Associated Skin Care Professionals (ASCP):    Associated Skin Care Professionals (ASCP) is the nation's largest association for skin care professionals and your ONLY all-inclusive source for professional liability insurance, education, community, and career support. For estheticians at every stage of the journey, ASCP is your essential partner. Get in touch with us today if you have any questions or would like to join and become an ASCP member.  Connect with ASCP:  Website: www.ascpskincare.com  Email: getconnected@ascpskincare.com  Phone: 800-789-0411  Facebook: facebook.com/ASCPskincare  Instagram: @ascpskincare     

Gareth and Ted are back for another run of Tech Addicts Podcasts. This week ChatGPT round your neck, A portable Hi-Fi, the iPhone Fold, Anker earbuds that power your phone, Acer's dazzling array of new devices, Redmagic making a 9 inch tablet and the MSI Claw portable gaming system. With Gareth Myles and Ted Salmon Join us on Mewe RSS Link: https://techaddicts.libsyn.com/rss  iTunes | YouTube Music | Stitcher | Tunein | Spotify  Amazon | Pocket Casts | Castbox | PodHubUK Feedback, Fallout and Contributions The MeWe Group member cry in unison “it has been too long”

In the first episode of a special daily series during the 2025 ASCO Annual Meeting, Dr. John Sweetenham discusses the results of 2 studies on the treatment of advanced colorectal cancer plus an additional study exploring the association of Medicaid expansion with cancer survival outcomes. Transcript Dr. John Sweetenham: Hello, and welcome to our special coverage of the 2025 ASCO Annual Meeting on the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'll be bringing you brief analysis on selected abstracts from each day of the Meeting. My disclosures are available in the transcript of this episode.  Today, I'll be reviewing three abstracts, the first two of which address the treatment of advanced colorectal cancer. Today's first study is Abstract 3501. These data were presented by Dr. Heinz-Josef Lenz from the USC Norris Comprehensive Cancer Center and report on the expanded analysis of the CheckMate-8HW trial. This was a phase 3, international, multicenter trial in patients with MSI-high/MMR-deficient metastatic colorectal cancer, who were randomized between nivolumab (nivo) alone, nivolumab plus ipilumomab (ipi) or investigators' choice of chemotherapy (FOLFOX or FOLFIRI) with or without bevacizumab or cetuximab. The study showed that nivo plus ipi demonstrated superior progression-free survival compared with chemotherapy in the first-line setting and superior progression-free survival compared with nivo alone across all lines of therapy. These results led to the approval of nivo + ipi in the first-line setting in patients with MSI-H/dMMR mCRC in the U.S., the EU, and many other countries.  In today's presentation, Dr. Lenz reported on the expanded analyses of nivo plus ipi versus nivo across all lines of therapy and longer follow-up results for nivo and ipi versus chemo in the first-line setting. With longer follow up (the median is now at 47 months) nivo and ipi continued to show progression-free survival benefit compared with chemotherapy with a median PFS of 54.1 months versus 5.9 months, for a hazard ratio of 0.21.  Additionally, the analysis of the effects on PFS2, defined as the time from randomization to progression after subsequent systemic therapy, start of second subsequent systemic therapy, or death, showed that compared with chemotherapy, first-line nivo and ipi was associated with a 72% reduction in the risk of death or disease progression, despite the fact that 71% of those who progressed following chemotherapy crossed over to receive subsequent immunotherapy. The study also showed that across all lines, nivo and ipi demonstrated superior progression-free survival compared with nivo alone, the median not reached versus 39.3 months, for a hazard ratio of 0.62. No new toxicity signals emerged after further analysis. Most treatment-related adverse events with possible immune etiology were observed within the first six months of therapy. The results for PFS2 are particularly significant. Up to now, there has been some reluctance to use nivo and ipi as first-line therapy, partly because of its toxicity profile and based on the rationale that it would be active after other frontline therapies. The observation in this study that the beneficial effects of nivo and ipi are maintained downstream is compelling. The results suggest that delaying the use of this combination to the second line or later may compromise subsequent PFS and supports the use of nivo and ipi as a standard-of-care frontline option for MSI-H/dMMR metastatic colorectal cancer. Moving on, the next study I'm featuring today is Abstract 3503, presented by Dr. Jeanne Tie from the Peter MacCallum Cancer Centre and the Walter and Eliza Hall Medical Institute of Medical Research from Melbourne, Australia. This study reported the impact of circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy escalation in stage III colon cancer, focused on the primary analysis of the ctDNA-positive cohort from the randomized DYNAMIC-III trial. As background, about 30% of patients with stage III colon cancer will recur following standard-of-care adjuvant therapy with oxaliplatin-based regimens. And current data show that for those patients with high-risk disease, 6 months of chemotherapy is associated with a lower recurrence rate than 3 months. Circulating tumor DNA following initial surgery has been shown to be a strong independent prognostic factor for these patients, but questions remain about how ctDNA can be used for adaptation of treatment. Questions regarding treatment adaptation were addressed in the DYNAMIC-III trials – specifically, does treatment escalation benefit those who are ctDNA positive following surgery, and can therapy be de-escalated for those who are ctDNA negative. The first of these 2 questions – treatment escalation in the positive group – is the subject of this report. One thousand and two patients were randomized in this study, between ctDNA-informed therapy (502) or standard management (500). Of those patients included in the intent to treat cohorts, 129 were ctDNA positive in the ctDNA-informed arm compared with 130 in the standard management arm. Various pre-planned treatment escalation protocols were used, depending on the choice of first-line therapy. With a median follow up of 42.2 months, there was no difference in 3-year relapse free survival between the ctDNA informed group (48%) and the standard management group (52%). There was, however, a highly significant difference in relapse-free survival for patients who cleared ctDNA by the end of treatment compared with those who didn't. The authors concluded that the recurrence risk for this group remains high, at about 50%, after adjuvant therapy and that it increases with higher ctDNA burden, but treatment escalation didn't appear to reduce the recurrence risk. Clearance of ctDNA was associated with a favorable outcome, suggesting that as more effective treatments are developed in the future for this group, ctDNA will likely prove to have major utility. Changing gears now, my final selection for today is Abstract 11006, presented by Dr. Elizabeth Shafer from the American Cancer Society. This study explored the association of Medicaid expansion with 5-year survival after a cancer diagnosis.  Dr. Schafer began her presentation by providing some historical perspective on the impact of the Affordable Care Act on reducing the number of uninsured adults aged less than 65 years in the United States. She then reviewed some recent data on the impact of Medicaid expansion on cancer care, including improved screening rates, improved access to cancer surgery, and an increase in earlier cancer diagnosis. The current study builds on earlier data from the American Cancer Society which showed improved 2-year overall survival for patients with newly diagnosed cancer following Medicaid expansion. The new study reported by Dr. Schafer examined 5-year cause-specific survival in individuals with cancer since Medicaid expansion, analyzed according to cancer type and various demographic and social factors. Using data from more than 813,000 individuals from 26 states that expanded Medicaid compared with more than 610,000 from 12 states that did not, the authors reported that similar improvements in 5-year cause-specific survival were observed in the expansion and the non-expansion states, but when analyzed by other factors, differences in outcome emerged. For example, although similar improvements in survival between expansion and non-expansion states were seen in urban communities, there was a significant improvement of 2.55 percentage points in survival for individuals in rural communities in expansion states compared with those in non-expansion states. Similar trends were observed in high poverty areas, where improvements in survival were superior in expansion versus non-expansion states.  When examined by cancer type, the authors observed greater improvements in 5-year survival for those with pancreatic, lung, and colorectal cancer, possibly due to improvements in screening and early access to treatment.  The authors concluded that those residing in rural and high-poverty areas experienced the most improvement in cause-specific cancer survival following Medicaid expansion. In summary, it's encouraging to see an improving trend in cancer mortality overall, independent of Medicaid expansion, but it's also important to remember that this is yet another study which confirms how implementation of the ACA has improved cancer outcomes and begun to address some of the disparities in cancer care. Join me again tomorrow to hear more top takeaways from ASCO25. And if you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.     Find out more about today's speaker:  Dr. John Sweetenham    Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn        Disclosures:  Dr. John Sweetenham:  No relationships to disclose 

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.Het weekend loopt zo je leven binnen op deze vrijdag. En we zijn er zoals zo vaak best aan toe. Even een paar dagen vrij en genieten van het vrije leven en wie weet een potje Elden Ring Nightreign. Dus laat maar komen die zaterdag en zondag. Vrijdag is ook het moment waarop jullie een nieuwe editie van Einde van de Week Live voorschotelen. De talkshow waarin drie hosts het game-gerelateerde nieuws van de week doornemen. Achter de desk zitten dit keer Jelle, JJ & Koos. Onderwerpen die de revue gaan passeren, zijn onder andere het cancellen van Black Panther, een bizar nieuw besturingsmechanisme voor de iPhone, een ‘blokkerige' trailer van GTA 6 en de tegenvallende kijkcijfers van The Last of Us 2, Dit alles en nog veel meer kun consumeren in de Einde van de Week Live van vrijdag 30 mei 2025.Eerste seizoen The Last of Us Season 2 verliest 50% kijkersWat velen van ons op de redactie een meer dan briljante game vonden, slaat op de TV een stuk minder aan. De laatste aflevering van The Last of Us Season 2 is echt stukken minder goed bekeken dan de laatste episode van het eerste seizoen. Waar komt dat door? De heren gaan erover in beraad. Ze kijken ook naar een bizarre PC mod die EA probeert weg te houden van The Sims 4. Wat is daar aan de hand? Plus klopt het dat mensen betaald worden om de game MindsEye van GTA-creator Lesley Benzies te slopen? Je krijgt de antwoorden in deze video.Pak 100 korting op deze powerhouse: de Vector 16 HX AI gaming laptopMSI zet deze week de Vector 16 HX AI in de spotlights. Deze fijne en zeer krachtige gaming laptop bezit een Intel Core Ultra 7 Processor (series 2), een NVIDIA GeForce RTX 5070 Ti videokaart, een 240Hz QHD+ display, een 1TB SSD en een 24-zone RGB toetsenbord. De Vector 16 HX AI is op de website van MeGekko verkrijgbaar met een korting van 100 euro: https://msi.gm/SCE20CD6 . Je krijgt er als bonus ook nog Dying Light en Civilization 7 bij.Check het concert van Nine Inch Nails op 29 mei in de Ziggo DomeOp 29 mei aanstaande kun je in de Ziggo Dome in Amsterdam het concert van de brute band Nine Inch Nails bijwonen. De muziek van de groep van frontman Trent Reznor, zal veel gamers bekend in de oren klinken, want het zit in vele games. Van de Call of Duty en Batman franchise tot Doom en Dead Island, de beukende sound van deze band heerst er. Wil je bij dit concert aanwezig zijn, dan kun je hier de kaarten scoren: https://www.mojo.nl/concerten/nine-inch-nails .Timestamps:00:00:00 EvdWL van 30 mei00:07:55 Huishoudelijke mededeling: MSI00:10:39 De nieuwe Cyberpunk is officieel in pre productie. CD Projekt Red toont wie aan wat werkt binnen studio.00:13:55 The Last of Us 2 serie raakt 50% kijkers kwijt00:22:53 EA stopt ontwikkeling Black Panther game en sluit de studio Cliffhanger. 00:28:31 Apple protocol over iPhones, iPads en Vision Pro besturen met je hersenen. 00:33:17 Nieuwe trailer van MindsEye. 00:37:18 Zelda film00:40:18 Sonic franchise brengt 1 miljard omzet naar Sega.00:42:33 GTA trailer met behulp van Lego 00:53:30 Ex Bethesda medewerker: Starfield voelde te steriel aan 00:55:26 BULLETTÎME: Nine Inch Nails 29 mei Ziggo Dome01:04:18 Releasedatum van Pokémon Legends Z/A is bekend.01:09:00 EA gaat de strijd aan met een opvallende mod…01:12:07 Clair Obscur: Expedition 3301:15:10 Crimson Desert 01:18:14 Project Milo01:23:33 COOL OF SERIOUS UNCOOL

Thorin and Peter Dun are joined by Enatron, currently the Head Coach for Ici Japon Corp. Esport, to discuss all of the upsets in the first round of LEC Playoffs, whether those upsets are a good or bad sign for the league going into MSI, Supa and Caps performing strongly, Oscarinin falling flat for Fnatic, and more!

Check Out PrizePicks! - https://prizepicks.onelink.me/ivHR/TRAVISTake a look at NZXT! - https://nzxt.co/travis ( Use code: travis5 )Follow Travis on Twitch: http://twitch.tv/travisgaffordSupport: https://linktr.ee/tgisupport00:00:00 Intro 00:19:19 Niicholodeon's take: With DSG benching scarry jerry it feels like rookies need to avoid the guest slot at all costs due to the immediate need to perform00:35:00 MissTimed's take: 100T vs. Shopify will be the most fun series next weekend00:46:40 NZXT break!00:50:20 basil's take: Shopify Rebellion is going to claw their way back to a revenge match against FLY01:06:45 narfidy's take: North America is about to have the worst MSI performance in history01:22:10 Outro

This episode of ASCP Esty Talk explores the FDA's controversial call for in vivo testing of chemical sunscreens and what it means for the future of skin care safety. We also unpack hot-button industry issues—from greenwashing and overmedicalization to fear-based marketing, barrier damage, and the lack of inclusive testing. Listen in to hear Ella and Maggie break down the facts behind the formulas. ASCP Esty Talk with hosts Ella Cressman and Maggie Staszcuk   Produced by Associated Skin Care Professionals (ASCP) for licensed estheticians, ASCP Esty Talk is a weekly podcast, hosted by licensed estheticians, Ella Cressman, ASCP Skin Deep Magazine contributor, and Maggie Staszcuk, ASCP Program Director. We see your passion, innovation, and hard work and are here to support you by providing a platform for networking, advocacy, camaraderie, and education. We aim to inspire you to ask the right questions, find your motivation, and give you the courage to have the professional skin care career you desire.  About Ella Cressman:  Ella Cressman is a licensed esthetician, certified organic formulator, business owner, ingredient junkie, and esthetic cheerleader! As an educator, she enjoys empowering other estheticians and industry professionals to understand skin care from an ingredient standpoint rather than a product-specific view.  In addition to running a skin care practice, Cressman founded a comprehensive consulting group, the HHP Collective, and has consulted for several successful skin care brands.    Connect with Ella Cressman:  Website: www.hhpcollective.com  LinkedIn: linkedin.com/in/ella-cressman-62aa46a    About Maggie Staszcuk:  Maggie Staszcuk serves as the Program Director for ASCP and is the cohost of ASCP Esty Talk podcast. With over 18 years' experience in the esthetics industry, her diverse background includes roles in spa management, spa and med-spa services, and esthetics education. Since becoming a licensed esthetician in 2006, she carries a range of certifications in basic and advanced esthetics. Maggie is dedicated to equipping estheticians with the knowledge and resources they need to thrive in their careers.   Connect with Maggie Staszcuk:  P: 800.789.0411 EXT 1636  E: MStaszcuk@ascpskincare.com    About our Sponsors:   The popular and revolutionary LAMPROBE utilizes radio and high-frequency technology to treat a wide variety of Minor Skin Irregularities™ (MSI)—non-invasively—with instantaneous results. Common conditions treated by the LAMPROBE include: vascular MSI, such as cherry angiomas; dilated capillaries; sebaceous MSI, including cholesterol deposits and milia; and hyperkerantinized MSI, such as keratoses and skin tags.   The LAMPROBE uniquely assists modern, capable, and skilled skin care practitioners to do their work more effectively and with greater client and professional satisfaction. Setting standards in quality, education, and training, the LAMPROBE has become an essential tool enabling skin care practitioners around the world to offer new revenue-enhancing and highly in-demand services.   Website: www.lamprobe.com   Email: info@lamskin.com   Phone: 877-760-2722   Instagram: www.instagram.com/lamprobe   Facebook: www.facebook.com/theLAMPROBE   TiZO Mineral Sunscreens set the standard for aesthetic elegance with tinted and non-tinted formulas for use on virtually all skin types and tones. Our name reflects our commitment: TIZO = Titanium dioxide + Zinc Oxides. All TiZO products are reef-friendly and 100% free of chemical sunscreens, dyes, fragrances, gluten, phthalates, and parabens.  TiZO Photoceutical Skincare is the perfect partner to our sunscreens in the fight against photoaging. These silky, elegant products address tone, texture and hydration while helping to prevent further damage. From our flagship TiZO3 Primer/Sunscreen SPF 40 to our gentle Ultra Zinc formulations to our NEW Advanced Vitamin C+E Serum with Bakuchiol, TIZO has the ideal selection of products to Protect, Repair, and Revitalize skin.  Website: https://tizoskin.com/  Facebook: @tizoskin  Pinterest: @tizoskin  Instagram: @tizoskin  YouTube: @tizoskin     Massage Envy is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services. Founded in 2002, Massage Envy now has approximately 1,100 franchise locations in 49 states that have together delivered more than 200 million massages and skin care services. Website: www.massageenvy.com/careers/career-areas/esthetician  Facebook: @MassageEnvyCareers LinkedIn: @MassageEnvy   About Associated Skin Care Professionals (ASCP):    Associated Skin Care Professionals (ASCP) is the nation's largest association for skin care professionals and your ONLY all-inclusive source for professional liability insurance, education, community, and career support. For estheticians at every stage of the journey, ASCP is your essential partner. Get in touch with us today if you have any questions or would like to join and become an ASCP member.  Connect with ASCP:  Website: www.ascpskincare.com  Email: getconnected@ascpskincare.com  Phone: 800-789-0411  Facebook: facebook.com/ASCPskincare  Instagram: @ascpskincare   

In a new Summoning Insight, Thorin and Yamato discuss GenG's dominance in the LCK, the thrilling LEC Playoffs, drama in the LEC All-Pro voting, T1 and their chances to qualify MSI, potential players to join Faker and Uzi in the Hall of Legends, and more! ​Shop the Into the AM Memorial Day Sale with up to 70% OFF until June 1. Save an additional 10% by using our link: https://intotheam.com/LFN. Get the ultimate immersive gaming experience with Turtle Beach today! For a limited time only, head to https://TurtleBeach.com and use Code SUMMONING for 10% off your entire order. Get 50% off FACTOR meals at https://www.factormeals.com/lfn50off with code lfn50off. High-quality, never-frozen meals delivered to your home!

Want to win some MSI Swag along with an MSI MPG Z890 Carbon WiFi Motherboard? Here's how: Take a picture of your custom build using an MSI component, and include a handwritten note with your discord username along with “DLC Podcast” in the picture. Then, join the MSI Discord (https://discord.gg/msi) and submit your entry in the #podcast-channel. This week, Jeff and Christian welcome Mike Futter from the Virtual Economy podcast back to the show to discuss the state of the industry based on Circana's April sales report, Fortnite making its triumphant return to iOS, USB mice support for Switch 2, and more! The Playlist: Mike: Blue Prince, Power Rangers: Rita Rewind, TMNT: Tactical Takedown, Clair Obscur: Expedition 33 Christian: Blades of Fire demo, Star Wars Outlaws - A Pirate's Fortune DLC  Jeff: Demos: Cast n Chill, Artis Impact, Jump the Track, Oscuro Blossom's Glow, Rue Valley, Future Vibe Check Tabletop Time: Mike: Token Terrors Battlegrounds, Re;Act, Apropos of Movies, Overpower CCG Jeff: Dragonkeepers Parting Gifts!

In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Nicholas Hornstein, a GI medical oncologist from Northwell Health, to discuss the recent FDA approval of nivolumab and ipilimumab for metastatic colorectal cancer with MSI-high or MMR-deficient disease, based on the CheckMate 8HW study. Join us as we delve into: •⁠  ⁠The significance of MSI-high status in colorectal cancer and its prevalence. •⁠  ⁠The study design and key findings of CheckMate 8HW, including the impressive progression-free survival rates. •⁠  ⁠The comparison of dual checkpoint inhibitors versus single-agent therapies and chemotherapy. •⁠  ⁠Important side effects associated with the combination therapy and how to manage them. •⁠  ⁠Insights on patient selection for immunotherapy, including considerations for age and comorbidities. •⁠  ⁠The potential future of immunotherapy in treating not just MSI-high but also MSS colorectal cancer. Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of cancer treatment. YouTube: https://youtu.be/wJRlECiY2VA Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our previous episodes for more discussions on FDA approvals, conference highlights, and treatment algorithms. We look forward to seeing you at ASCO 2025! #OncologyBrothers #CancerPodcast #Immunotherapy #ColorectalCancer #FDAApproval #CheckMate8HW

This week, Federico drops a big gaming surprise on John after the two of them cover the latest Switch 2, MSI, and Anbernic handheld news. Also available on YouTube here. Links and Show Notes The Latest Portable Gaming News Nintendo Samsung making its chips at potentially higher volumes than expected Nintendo Turns to Samsung to Make Chips, Ramp Up Switch 2 Production Mario Kart World originally planned for OG Switch Ask the Developer Vol. 18 Mario Kart World — Part 1 SteamOS Valve's huge Steam Deck update is now ready for everyone, including rival AMD handhelds How To Install SteamOS On The ROG Ally And ROG Ally X Handhelds Anbernic RG34XXSP First Impressions Big Forehead, Bigger Potential Screen Shenanigans? UPDATE Anbernic Responds Anbernic RG34XXSP's ‘Five-Head' Bezel Masks a True 43 Screen MSI Claw A8 MSI Claw A8 handheld gaming PC has a Ryzen Z2 Extreme chip with 16-core graphics - Liliputing MSI Claw A8 with AMD Ryzen Z2 Extreme Debuts at Computex 2025 MSI's new handheld gaming PC ditches Intel for AMD Thunderbolt 5 eGPUs It's still early but the TB5 eGPUs are coming Lilbits Asus ROG XG Station eGPU dock with Thunderbolt 5, AYANEO Flip 1S handheld gaming PC, and Microsoft's new command line text editor Sparkle unveils Studio-G Ultra 850, its first Thunderbolt 5 eGPU solution - [Gigabyte presents AORUS AI BOX, GeForce RTX 5090 desktop GPU with Thunderbolt 5](https://videocardz.com/newz/gigabyte-presents-aorus-ai-box-geforce-rtx-5090-desktop-gpu-with-thunderbolt-5)   A Very Ticci Surprise Inside Tech Lian Li A3 Razer PC Remote Play Officially Launches Subscribe to NPC XL NPC XL is a weekly members-only version of NPC with extra content, available exclusively through our new Patreon for $5/month. Each week on NPC XL, Federico, Brendon, and John record a special segment or deep dive about a particular topic that is released alongside the “regular” NPC episodes. You can subscribe here: https://www.patreon.com/c/NextPortableConsole Leave Feedback for John, Federico, and Brendon NPC Feedback Form Credits Show Art: Brendon Bigley Music: Will LaPorte Follow Us Online On the Web MacStories.net Wavelengths.online Follow us on Mastodon NPC Federico John Brendon Follow us on Bluesky NPC MacStories Federico Viticci John Voorhees Brendon Bigley Affiliate Linking Policy: https://www.macstories.net/privacy-policy/    

No more misinformation - AMD finally announced their Radeon RX 9060 XT, and it turns out that reports of a $449 MSRP were greatly exaggerated. And what the heck is going on with Ryzen and EPYC right now? We have EPYC branded Ryzen desktop chips, and Ryzen branded EPYC chips for workstations (gross oversimplification)?!  Developers! (get fired), Silverstone retro, and also there's a clipboard.Timestamps:00:00 Intro01:45 Food with Josh03:57 Radeon RX 9060 XT announced, starts at 299 USD08:53 Threadripper 900012:07 Crucial's T710 Gen5 SSD announced13:54 Microsoft injecting "ai" into File Explorer21:36 A new dual-GPU graphics card in 2025??26:27 SilverStone adds FLP02 to retro case lineup29:14 MS brings back the DOS-era Edit program31:18 Netflix plans generative "ai" ads during streams in 202633:59 Podcast sponsor NordLayer35:29 (in)Security Corner53:49 Gaming Quick Hits59:00 Kent's NZXT H3 Flow mATX case review1:09:46 A quick look at MSI's RTX 5070 GAMING TRIO OC1:16:48 Picks of the Week ★ Support this podcast on Patreon ★

-Randy Pitchford can't read the room: https://www.ign.com/articles/as-gamers-express-concern-about-borderlands-4-potentially-costing-80-gearbox-chief-randy-pitchford-says-if-youre-a-real-fan-youll-find-a-way-to-make-it-happen -MSI doing an AMD Claw: https://www.theverge.com/news/670096/msi-claw-a8-amd-z2-extreme-computex-2025 -Bungie is looking bad: https://www.ign.com/articles/fans-discuss-marathon-developer-bungies-future-after-yet-another-plagiarism-row-rocks-studio-make-no-mistake-this-is-an-existential-struggle-for-bungie-at-this-point -Did Epic win? https://www.theverge.com/news/661290/fortnite-ios-iphone-epic-games-back-apple-app-store https://daringfireball.net/linked/2025/05/19/the-first-rule-of-legal-fight-club -Game News:  Steller Blade coming to PC on June 11: https://www.engadget.com/gaming/pc/stellar-blade-heads-to-pc-on-june-11-185536164.html?src=rss Prince of Persia remake coming in early 2026: https://www.theverge.com/news/667061/ubisoft-prince-of-persia-remake-release-date-by-april-2026 New Uncharted coming!!!!!! https://comicbook.com/gaming/news/naughty-dog-new-game-confirmed-uncharted/ -Sony halting services in Russia. https://www.pravda.com.ua/eng/news/2025/05/19/7512924/ -Would you put steamOS on your ROG? https://arstechnica.com/gaming/2025/05/valve-adds-steamos-compatible-game-label-as-it-prepares-to-expand-beyond-steam-deck/

Panel:  @retrotechdad   @ban6756  AndrewRH  @StubbsStuff  This week's Full News and Sources: https://retrohandhelds.gg/retro-handhelds-weekly-edition-47/〰〰〰〰〰〰〰〰〰〰〰〰〰〰〰〰〰〰〰〰

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.Er staat ons een, hopelijk, fijn weekend te wachten. Lekker uitslapen, even ergens op een terras een kopje koffie drinken of een biertje pakken. Misschien wat vrienden bezoeken of gewoon op je gemak je back catalogue wegwerken. Dit vooruitzicht gaan we verder opvrolijken met een nieuwe aflevering van Einde van de Week Vrijdag Live. De talkshow waarin we elke week het belangrijkste game gerelateerde nieuws van de afgelopen zeven dagen met de kijkers doornemen. Huey, Jasper en Jelle zitten klaar om te kletsen over topics zoals de bizarre uitspraak van Randy Pitchford over de prijs van Borderlands 4, de nieuwe Cyberpunk game en Senua's Sage Hellblade 2 dat naar de PS5 komt. Plus retro fans kunnen aan de slag met een hele bups aan arcade classics via Game Pass. Dit alles en meer ga je zien en horen in de Einde van de Week Live van vrijdag 21 maart 2025.Randy Pitchford vindt vragen over prijs Borderlands 4 gezeurIn deze editie van onze wekelijkse afsluiter, gaan de drie ook in gesprek over Veo 3 van Google. Een nieuwe AI tool om video's te maken die er kwalitatief griezelig goed uit zien. Zijn de filmers, vormgevers en editors straks allemaal hun baan kwijt?Pak 160 euro korting bij aanschaf MSI Cyborg 15 gaming laptopDeze week zet MSI de alom bekende Cyborg 15 in het zonnetje. Deze gaming laptop is namelijk met dank aan de vakantiegeld promoties van Bol hier afgeprijsd naar 839 euro: https://msi.gm/S7B41F68 . En wat krijg je dan? Een laptop met aan boord een 13e generatie Intel Core i7 processor, een RTX 4060 videokaart, een 512GB SSD, een 144Hz Full HD panel en een 4-zone RGB toetsenbord.Timestamps00:00:00 Einde van de Week Live van 23 mei00:00:17 Huishoudelijke mededeling: MSI00:02:30 Wat hebben we deze week gedaan?00:09:53 Elden Ring gaat verfilmd worden (live action).00:18:23 Randy Pitchford over 80 euro voor Borderlands 4.00:22:53 Cyberpunk 2077 krijgt nieuwe stad, die aanvoelt als ‘Chicago gone wrong'.00:37:20 PlayStation stopt met het loyaliteitsprogramma PlayStation Stars.00:40:26 Senua's Saga Hellblade 2 komt deze zomer naar de PS5 (was Xbox game).00:51:30 Mario Kart Worlds was oorspronkelijk bedoeld voor de Switch.00:56:48 Openings cutscene Metal Gear Solid Delta Snake Eater is vrijgegeven.01:00:30 PAC-MAN bestaat deze week 45 jaar.01:04:08 Volgens insiders komt er een Bioshock aankondiging aan deze zomer.01:06:39 Embracer wil het komend jaar 76 verschillende games in de winkels leggen.01:10:11 Drie vormgevende mannen aan tafels geven hun mening over het nieuwe logo van Naughty Dog. 01:14:46 Google Veo 3 werd deze week geshowed.01:23:30 Wat zegt deze tweet je?01:25:37 94% van alle games die Capcom in 2024 verkocht waren digitale versies. Op PC was dit aantal bijna 100%, console 78%01:30:14 Nu te spelen op Game Pass, de Retro Classics van Activision.01:33:14 Durf jij dit of toch geen vertrouwen in zelfrijdende auto's?01:34:47 Welke heb je liever (beide controllers zijn vanaf deze week te koop)?01:36:01 Goede vraag...

Look out! Here comes Spider-Man – along with his villains and other well-known Spider-Verse characters. It's all part of a new immersive exhibition at the Griffin Museum of Science and Industry. It brings together a collection of artifacts, iconic moments from every era, and wall-to-wall artwork from Spider-Man's first comic book appearance in 1962. Reset learns more about the superhero's evolution and what the exhibition offers with Voula Saridakis, MSI's head curator. For a full archive of Reset interviews, head over to wbez.org/reset.

This week on ASCP Esty Talk, we're joined once again by the brilliant Sherrie Tennessee—a trailblazer at the intersection of wellness, beauty, and technology. With a PhD in hospitality administration and more than two decades of experience in wellness and spa management, Sherrie shares how modern innovations are transforming self-care practices at home. Tune in as Ella and Maggie explore the evolving landscape of wellness tech and its powerful impact on the professional esthetics industry. ASCP Esty Talk with hosts Ella Cressman and Maggie Staszcuk   Produced by Associated Skin Care Professionals (ASCP) for licensed estheticians, ASCP Esty Talk is a weekly podcast, hosted by licensed estheticians, Ella Cressman, ASCP Skin Deep Magazine contributor, and Maggie Staszcuk, ASCP Program Director. We see your passion, innovation, and hard work and are here to support you by providing a platform for networking, advocacy, camaraderie, and education. We aim to inspire you to ask the right questions, find your motivation, and give you the courage to have the professional skin care career you desire.  About Ella Cressman:  Ella Cressman is a licensed esthetician, certified organic formulator, business owner, ingredient junkie, and esthetic cheerleader! As an educator, she enjoys empowering other estheticians and industry professionals to understand skin care from an ingredient standpoint rather than a product-specific view.  In addition to running a skin care practice, Cressman founded a comprehensive consulting group, the HHP Collective, and has consulted for several successful skin care brands.    Connect with Ella Cressman:  Website: www.hhpcollective.com  LinkedIn: linkedin.com/in/ella-cressman-62aa46a    About Maggie Staszcuk:  Maggie Staszcuk serves as the Program Director for ASCP and is the cohost of ASCP Esty Talk podcast. With over 18 years' experience in the esthetics industry, her diverse background includes roles in spa management, spa and med-spa services, and esthetics education. Since becoming a licensed esthetician in 2006, she carries a range of certifications in basic and advanced esthetics. Maggie is dedicated to equipping estheticians with the knowledge and resources they need to thrive in their careers.   Connect with Maggie Staszcuk:  P: 800.789.0411 EXT 1636  E: MStaszcuk@ascpskincare.com    About our Sponsors:   The popular and revolutionary LAMPROBE utilizes radio and high-frequency technology to treat a wide variety of Minor Skin Irregularities™ (MSI)—non-invasively—with instantaneous results. Common conditions treated by the LAMPROBE include: vascular MSI, such as cherry angiomas; dilated capillaries; sebaceous MSI, including cholesterol deposits and milia; and hyperkerantinized MSI, such as keratoses and skin tags.   The LAMPROBE uniquely assists modern, capable, and skilled skin care practitioners to do their work more effectively and with greater client and professional satisfaction. Setting standards in quality, education, and training, the LAMPROBE has become an essential tool enabling skin care practitioners around the world to offer new revenue-enhancing and highly in-demand services.   Website: www.lamprobe.com   Email: info@lamskin.com   Phone: 877-760-2722   Instagram: www.instagram.com/lamprobe   Facebook: www.facebook.com/theLAMPROBE   TiZO Mineral Sunscreens set the standard for aesthetic elegance with tinted and non-tinted formulas for use on virtually all skin types and tones. Our name reflects our commitment: TIZO = Titanium dioxide + Zinc Oxides. All TiZO products are reef-friendly and 100% free of chemical sunscreens, dyes, fragrances, gluten, phthalates, and parabens.  TiZO Photoceutical Skincare is the perfect partner to our sunscreens in the fight against photoaging. These silky, elegant products address tone, texture and hydration while helping to prevent further damage. From our flagship TiZO3 Primer/Sunscreen SPF 40 to our gentle Ultra Zinc formulations to our NEW Advanced Vitamin C+E Serum with Bakuchiol, TIZO has the ideal selection of products to Protect, Repair, and Revitalize skin.    Website: https://tizoskin.com/  Facebook: @tizoskin  Pinterest: @tizoskin  Instagram: @tizoskin  YouTube: @tizoskin     Massage Envy is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services. Founded in 2002, Massage Envy now has approximately 1,100 franchise locations in 49 states that have together delivered more than 200 million massages and skin care services. Website: www.massageenvy.com/careers/career-areas/esthetician  Facebook: @MassageEnvyCareers LinkedIn: @MassageEnvy   About Associated Skin Care Professionals (ASCP):    Associated Skin Care Professionals (ASCP) is the nation's largest association for skin care professionals and your ONLY all-inclusive source for professional liability insurance, education, community, and career support. For estheticians at every stage of the journey, ASCP is your essential partner. Get in touch with us today if you have any questions or would like to join and become an ASCP member.  Connect with ASCP:  Website: www.ascpskincare.com  Email: getconnected@ascpskincare.com  Phone: 800-789-0411  Facebook: facebook.com/ASCPskincare  Instagram: @ascpskincare   

Global reproductive rights and investment in the agencies and organizations that support reproductive rights have often been used as a political football. The bodies of women, girls, and LGBTQI+ persons have been used to push and pull power for decades—and this anti-rights, anti-choice framework has become increasingly exported around the world. Beth Schlachter, Senior Director for U.S. and External Engagement for MSI Reproductive Choices, talks to us about how attacks to human rights frameworks and funding will further endanger global reproductive health and rights.Some apparatuses the U.S. have been using to redefine human rights, and therefore, redefine access to sexual and reproductive healthcare services, include the Commission on Unalienable Rights, the International Ministerial Conference on Freedom of Religion or Belief, and the Geneva Consensus Declaration. These frameworks and tools then get internationally exported. MSI has a host of programs around the world that will be impacted by these tools, frameworks, and funding attacks. MSI's programs support maternal health and access to other reproductive health services. In addition, these attacks will likely and broadly impact child marriage programs, the PEPFAR program, the Sustainable Development Goals, and more.For more information check outThe Nocturnists: https://thenocturnists.org/Support the showFollow Us on Social: Twitter: @rePROsFightBack Instagram: @reprosfbFacebook: rePROs Fight Back Bluesky: @reprosfightback.bsky.social Email us: jennie@reprosfightback.comRate and Review on Apple PodcastThanks for listening & keep fighting back!

This week, we're sharing an interview with Garret Felber, author of the book A Continuous Struggle: The Revolutionary Life of Martin Sostre,  out May 5 from AK Press. Garret speaks about the life of Martin Soster, famed jailhouse lawyer who successfully won cases related to the constitutional rights of prisoners, was politicized in prison by the Nation of Islam in the 1950's, ran radical Afro-centric bookstores in Buffalo NY to radicalize the youth, embracing anarchism during his time imprisoned on a frame up during which he was a celebrated political prisoner resisting cavity searches through the courts, went on to organize after his release for tenants rights and rehabilitating disused buildings for community centers and helping run a childcare. Sostre was a mentor to Lorenzo Komb'oa-Ervin and Ashanti Alston and laid important foundations for modern Black Anarchism in the US. Transcript PDF (Unimposed) Zine (Imposed PDF) There's a lot in here and we hope you enjoy the book and that the story inspires complex, creative and combative resistance to all forms of domination.   MSI: https://www.martinsostre.com/ Study and Struggle: https://www.studyandstruggle.com/ Those Who Know Don't Say: The Nation Of Islam, the Black Freedom Movement, and the Carceral State Free the Mississippi Five: https://www.studyandstruggle.com/ms5 Free Society People's Library: https://www.instagram.com/freesocietylibrary/ Justice for Geraldine and Martin: https://www.instagram.com/justiceforgeraldineandmartin/ In the Belly: https://www.bellyzine.net/ In the Mix: https://inthemixprisonerpodcast.libsyn.com/ video of JEEP: https://www.youtube.com/watch?v=UwmELJwEsk8 Some past episodes touching on Black anarchism: Black Autonomy Reader: https://thefinalstrawradio.noblogs.org/post/2024/09/29/mutt-on-the-incomplete-black-autonomy-reader/ Ashanti Alston at ACAB2024: https://thefinalstrawradio.noblogs.org/post/2024/09/01/solidarity-spirituality-and-liberatory-promise-on-a-turtles-back-with-ashanti-omowali-alston/ Matt Meyer on Kuwasi Balagoon: https://thefinalstrawradio.noblogs.org/post/2019/06/04/free-them-all-matt-meyer-on-kuwasi-balagoon/ Lorenzo Kom'boa Ervin: https://thefinalstrawradio.noblogs.org/post/2013/04/03/memphis-organizes-against-police-and-the-kkk-a-conversation-with-lorenzo-komboa-ervin/ William C Anderson (first & second) Announcement Kevin Rashid Johnson From the SFBayView Newspaper: Rashid was “compacted” on May 1 to the Perry Correctional Institution in South Carolina, 430 Oaklawn Rd., Pelzer, SC 29669. His ID number in South Carolina is 397279. In the transit van, he was severely injured – probably a broken bone – in his left leg. He has not been given any treatment for it. He is in solitary confinement, with only a concrete slab to sleep on. He can make only one phone call per week. A comrade is helping him get onto the “GTL Getting Out” app so that he can communicate with everyone. Meanwhile, he has been on hunger strike since he got there. He lost 17 pounds during the first week. He appeals for maximum publicity and pressure. The phone numbers listed for the prison are: 864-243-4700 and 803-737-1752. Make calls and spread the word. Kevin “Rashid” Johnson, ID number 397279, must be treated humanely, given good medical care and a decent place to sleep and allowed full access to communicate with his lawyers and supporters. Tell the authorities to meet his demands so he can end his hunger strike. . ... . .. Featured Track Standing At The Crossroad by Eddie and Ernie from Lost Friends

I sit down with Marina Udier, CEO of Nouscom, a Swiss company working on the Lynch Syndrome vaccine.  Nous209 is designed to intercept tumors in Lynch Syndrome cancers.  The 209 comes from the frameshifts of neoantigens, whether sporadic or hereditary.  Idea is to educate the T-cells before cancers start forming.  The data at AACR presented was very promising.  They are also running a study on metastatic colorectal cancer patients, mostly without Lynch Syndrome, but MSI high.  So how many people are tested positive for Lynch Syndrome each year?  Next steps includes additional investigators and patients for a much bigger trial, at a time to be determined, and of course funding is always a priority.  Suffice it so say, interest is high is seeing this come to late stage development.    

Timestamps: 0:00 See ya on Wed, May 21 0:09 Epic's plan for Apple to block Fortnite 3:29 Intel Arc Pro B60, RX 9060 XT 4:27 OpenAI Codex, Grok's breakdown 5:50 MSI! 6:41 QUICK BITS INTRO 6:47 Spotify podcast play counts 7:14 The Steam data breach that wasn't 7:41 Australian rocket top fell off 8:07 BREAKING: Vader is bad guy NEWS SOURCES: https://lmg.gg/oRJxT Learn more about your ad choices. Visit megaphone.fm/adchoices

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.Het belooft een lekker voorportaal van het aanstaande weekend te gaan worden. Een vrijdag waar de thermometer rond de 20 graden uit komt. Lekker zonnetje erbij. Niet te warm, niet te koud. Logisch dat de stemming er in zit in de studio. Jelle, Huey en Koos zitten klaar om een nieuwe editie op te nemen van Einde van de Week Live. De talkshow waarin we week-in-week-uit het belangrijkste game gerelateerde nieuws met de kijkers doornemen. Topics zijn deze keer onder meer een klein schandaal rond het artwork van Marathon. Verder de reden voor het uitstel van GTA 6 en het uitstel van Marvel 1943: Rise of Hydra. Dit alles en meer ga je zien en horen in de Einde van de Week Live van vrijdag 16 mei 2025.'GTA 6 uitgesteld om creatieve visie zonder limieten uit te voeren'Andere onderwerpen die in deze show behandeld worden, zijn de naam van de nieuwe Mario movie en MAX dat opeens weer HBO Max gaat heten. Ook bespreken ze de vermeende hack bij Steam. Plus ze praten over Jade Raymond die opeens weg gaat bij Haven Studios, een studio die een game maakte voor PlayStation.Scoor fijne korting én drie gratis games bij aankoop MSI Vector 16 HX AI gaming laptopDeze week zet MSI de Vector 16 HX AI in de spotlights. Deze krachtige gaming laptop herbergt een Intel Core Ultra 9 HX processor en een NVIDIA RTX 5080 videokaart. Verder krijg je een QHD+ 240Hz 16-inch scherm, 1TB aan opslag en een 24-zone RGB toetsenbord. Met dank aan MeGekko kun je deze krachtpatser hier met een fijne korting aanschaffen. Met als bonus de medeneming van de games Dying Light, Civilization 7 en Doom: The Dark Ages in huis halen.Timestamps:00:00:00 Einde van de Week Live van 16 mei00:00:24 Huishoudelijke mededeling: MSI00:05:45 Marvel 1943: Rise of Hydra uitgesteld naar 2026.00:15:23 Schandaal rond Bungies Marathon.00:21:53 GTA 6 is volgens baas Take Two uitgesteld, om de creatieve visie voor het spel te behalen zonder limitaties.00:30:32 Jade Raymond verlaat Haven Studio's waar ze een shooter voor PlayStation maakte, genaamd Fair Games. 00:35:46 Zenimax heeft de trademarks vernieuwd voor de IP's van Wolfenstein, Deathloop, Quake en Dishonored.00:40:17 Kojima heeft een USB stick vol ideeen aan zijn persoonlijke assistent gegeven voor het geval hij komt te overlijden.00:46:19 Resident Evil 9 wordt mogelijk tijdens Summer Game Fest aangekondigd en komt in 2026 uit.00:50:52 Als The Edge, het meest kritische games magazine ter wereld, een tien aan een game geven, heb je als developer iets uitzonderlijks gepresenteerd. 00:56:52 XboxEra, een grote podcast als het gaat om Xbox nieuws, willen de term Xbox uit hun naam slopen.01:01:19 Ubisoft heeft aangegeven dat Prince of Persia Sands of Time uitkomt tussen januari en maart 2026.01:03:59 Nieuwe Mario film zou Super Mario World heten.01:08:37 MAX wordt toch weer HBO Max01:10:02 Dillema's

GLP-1 RA medications like Ozempic and Wegovy are transforming more than waistlines—they're reshaping beauty standards and creating new challenges and opportunities in skin care. Rapid weight loss can lead to loose skin, facial volume loss, and dehydration, making professional esthetics care more important than ever. This episode of ASCP Esty Talk explores how skin care pros can support clients through these changes with treatments that restore, tighten, and celebrate their evolving bodies. ASCP Esty Talk with hosts Ella Cressman and Maggie Staszcuk   Produced by Associated Skin Care Professionals (ASCP) for licensed estheticians, ASCP Esty Talk is a weekly podcast, hosted by licensed estheticians, Ella Cressman, ASCP Skin Deep Magazine contributor, and Maggie Staszcuk, ASCP Program Director. We see your passion, innovation, and hard work and are here to support you by providing a platform for networking, advocacy, camaraderie, and education. We aim to inspire you to ask the right questions, find your motivation, and give you the courage to have the professional skin care career you desire.  About Ella Cressman:  Ella Cressman is a licensed esthetician, certified organic formulator, business owner, ingredient junkie, and esthetic cheerleader! As an educator, she enjoys empowering other estheticians and industry professionals to understand skin care from an ingredient standpoint rather than a product-specific view.  In addition to running a skin care practice, Cressman founded a comprehensive consulting group, the HHP Collective, and has consulted for several successful skin care brands.    Connect with Ella Cressman:  Website: www.hhpcollective.com  LinkedIn: linkedin.com/in/ella-cressman-62aa46a    About Maggie Staszcuk:  Maggie Staszcuk serves as the Program Director for ASCP and is the cohost of ASCP Esty Talk podcast. With over 18 years' experience in the esthetics industry, her diverse background includes roles in spa management, spa and med-spa services, and esthetics education. Since becoming a licensed esthetician in 2006, she carries a range of certifications in basic and advanced esthetics. Maggie is dedicated to equipping estheticians with the knowledge and resources they need to thrive in their careers.   Connect with Maggie Staszcuk:  P: 800.789.0411 EXT 1636  E: MStaszcuk@ascpskincare.com    About our Sponsors:   The popular and revolutionary LAMPROBE utilizes radio and high-frequency technology to treat a wide variety of Minor Skin Irregularities™ (MSI)—non-invasively—with instantaneous results. Common conditions treated by the LAMPROBE include: vascular MSI, such as cherry angiomas; dilated capillaries; sebaceous MSI, including cholesterol deposits and milia; and hyperkerantinized MSI, such as keratoses and skin tags.   The LAMPROBE uniquely assists modern, capable, and skilled skin care practitioners to do their work more effectively and with greater client and professional satisfaction. Setting standards in quality, education, and training, the LAMPROBE has become an essential tool enabling skin care practitioners around the world to offer new revenue-enhancing and highly in-demand services.   Website: www.lamprobe.com   Email: info@lamskin.com   Phone: 877-760-2722   Instagram: www.instagram.com/lamprobe   Facebook: www.facebook.com/theLAMPROBE   TiZO Mineral Sunscreens set the standard for aesthetic elegance with tinted and non-tinted formulas for use on virtually all skin types and tones. Our name reflects our commitment: TIZO = Titanium dioxide + Zinc Oxides. All TiZO products are reef-friendly and 100% free of chemical sunscreens, dyes, fragrances, gluten, phthalates, and parabens.  TiZO Photoceutical Skincare is the perfect partner to our sunscreens in the fight against photoaging. These silky, elegant products address tone, texture and hydration while helping to prevent further damage. From our flagship TiZO3 Primer/Sunscreen SPF 40 to our gentle Ultra Zinc formulations to our NEW Advanced Vitamin C+E Serum with Bakuchiol, TIZO has the ideal selection of products to Protect, Repair, and Revitalize skin.  Website: https://tizoskin.com/  Facebook: @tizoskin  Pinterest: @tizoskin  Instagram: @tizoskin  YouTube: @tizoskin     Massage Envy is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services. Founded in 2002, Massage Envy now has approximately 1,100 franchise locations in 49 states that have together delivered more than 200 million massages and skin care services. Website: www.massageenvy.com/careers/career-areas/esthetician  Facebook: @MassageEnvyCareers LinkedIn: @MassageEnvy   About Associated Skin Care Professionals (ASCP):    Associated Skin Care Professionals (ASCP) is the nation's largest association for skin care professionals and your ONLY all-inclusive source for professional liability insurance, education, community, and career support. For estheticians at every stage of the journey, ASCP is your essential partner. Get in touch with us today if you have any questions or would like to join and become an ASCP member.  Connect with ASCP:  Website: www.ascpskincare.com  Email: getconnected@ascpskincare.com  Phone: 800-789-0411  Facebook: facebook.com/ASCPskincare  Instagram: @ascpskincare   

From flapper-era razors to vajacials and TikTok trends, this episode of ASCP Esty Talk is all about the wild ride of intimate grooming over the past 100 years, influenced by shifts in fashion, media, and cultural norms. From the rise of leg shaving in the 1920s to the introduction of Brazilian waxing in the '80s, we dive into how fashion, pop culture, and body positivity shaped everything from bikini lines to body autonomy to understanding how intimate care became a reflection of personal and cultural identity. Spoiler alert: The hottest trend right now—doing whatever makes you feel fabulous! ASCP Esty Talk with hosts Ella Cressman and Maggie Staszcuk   Produced by Associated Skin Care Professionals (ASCP) for licensed estheticians, ASCP Esty Talk is a weekly podcast, hosted by licensed estheticians, Ella Cressman, ASCP Skin Deep Magazine contributor, and Maggie Staszcuk, ASCP Program Director. We see your passion, innovation, and hard work and are here to support you by providing a platform for networking, advocacy, camaraderie, and education. We aim to inspire you to ask the right questions, find your motivation, and give you the courage to have the professional skin care career you desire.  About Ella Cressman:  Ella Cressman is a licensed esthetician, certified organic formulator, business owner, ingredient junkie, and esthetic cheerleader! As an educator, she enjoys empowering other estheticians and industry professionals to understand skin care from an ingredient standpoint rather than a product-specific view.  In addition to running a skin care practice, Cressman founded a comprehensive consulting group, the HHP Collective, and has consulted for several successful skin care brands.    Connect with Ella Cressman:  Website: www.hhpcollective.com  LinkedIn: linkedin.com/in/ella-cressman-62aa46a    About Maggie Staszcuk:  Maggie Staszcuk serves as the Program Director for ASCP and is the cohost of ASCP Esty Talk podcast. With over 18 years' experience in the esthetics industry, her diverse background includes roles in spa management, spa and med-spa services, and esthetics education. Since becoming a licensed esthetician in 2006, she carries a range of certifications in basic and advanced esthetics. Maggie is dedicated to equipping estheticians with the knowledge and resources they need to thrive in their careers.   Connect with Maggie Staszcuk:  P: 800.789.0411 EXT 1636  E: MStaszcuk@ascpskincare.com    About our Sponsors:   The popular and revolutionary LAMPROBE utilizes radio and high-frequency technology to treat a wide variety of Minor Skin Irregularities™ (MSI)—non-invasively—with instantaneous results. Common conditions treated by the LAMPROBE include: vascular MSI, such as cherry angiomas; dilated capillaries; sebaceous MSI, including cholesterol deposits and milia; and hyperkerantinized MSI, such as keratoses and skin tags.   The LAMPROBE uniquely assists modern, capable, and skilled skin care practitioners to do their work more effectively and with greater client and professional satisfaction. Setting standards in quality, education, and training, the LAMPROBE has become an essential tool enabling skin care practitioners around the world to offer new revenue-enhancing and highly in-demand services.   Website: www.lamprobe.com   Email: info@lamskin.com   Phone: 877-760-2722   Instagram: www.instagram.com/lamprobe   Facebook: www.facebook.com/theLAMPROBE   TiZO Mineral Sunscreens set the standard for aesthetic elegance with tinted and non-tinted formulas for use on virtually all skin types and tones. Our name reflects our commitment: TIZO = Titanium dioxide + Zinc Oxides. All TiZO products are reef-friendly and 100% free of chemical sunscreens, dyes, fragrances, gluten, phthalates, and parabens.  TiZO Photoceutical Skincare is the perfect partner to our sunscreens in the fight against photoaging. These silky, elegant products address tone, texture and hydration while helping to prevent further damage. From our flagship TiZO3 Primer/Sunscreen SPF 40 to our gentle Ultra Zinc formulations to our NEW Advanced Vitamin C+E Serum with Bakuchiol, TIZO has the ideal selection of products to Protect, Repair, and Revitalize skin.  Website: https://tizoskin.com/  Facebook: @tizoskin  Pinterest: @tizoskin  Instagram: @tizoskin  YouTube: @tizoskin     Massage Envy is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services. Founded in 2002, Massage Envy now has approximately 1,100 franchise locations in 49 states that have together delivered more than 200 million massages and skin care services. Website: www.massageenvy.com/careers/career-areas/esthetician  Facebook: @MassageEnvyCareers LinkedIn: @MassageEnvy   About Associated Skin Care Professionals (ASCP):    Associated Skin Care Professionals (ASCP) is the nation's largest association for skin care professionals and your ONLY all-inclusive source for professional liability insurance, education, community, and career support. For estheticians at every stage of the journey, ASCP is your essential partner. Get in touch with us today if you have any questions or would like to join and become an ASCP member.  Connect with ASCP: Website: www.ascpskincare.com  Email: getconnected@ascpskincare.com  Phone: 800-789-0411  Facebook: facebook.com/ASCPskincare  Instagram: @ascpskincare 

The latest episode of the podcast features the musings of J. Hellstrom, background art by J. Hellstrom, and several segments written - in large part - by J. Hellstrom.  In a way, we are all Jeremy now.  Also within, find us talking about gyroscopes, no more Hyte, Copilot popularity and even 12VHPWR! As if.Timestamps:00:00 Intro01:03 Food with Josh02:30 Too early for RTX 50 Series SUPER rumors? 3GB modules say no!07:53 Intel Foundry Direct Connect 202517:18 The 40th anniversary of the Acorn RISC Machine (ARM)21:22 The tech we need to fight GPU sag23:10 HYTE pauses shipments to USA28:31 Copilot is so hot right now32:28 MSI's yellow 12VHPWR connectors turn black when they burn34:12 Yet another Project Kuiper update40:39 (in)Security Corner51:07 Gaming Quick Hits1:02:16 Picks of the Week1:16:06 Outro1:17:04 Jeremy did it ★ Support this podcast on Patreon ★

Dr. Rohan Garje shares the updated recommendations for the ASCO guideline on systemic therapy for patients with metastatic castration-resistant prostate cancer. He discusses the systemic therapy options for patients based on prior therapy received in the castration-sensitive and non-metastatic castration-resistant settings. He emphasizes personalizing treatment choices for each individual, considering patient-specific symptoms and signs, treatment-related toxicities, potential drug interactions, cost, and access. He also reviews recommendations on response assessment. The conversation wraps up with a discussion of potential future updates to this guideline, as the guideline transitions into a “living guideline” on mCRPC. Read the full guideline update, “Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update”. Transcript This guideline, clinical tools, and resources are available at www.asco.org/genitourinary-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology.      Brittany Harvey: Hello and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Rohan Garje from Miami Cancer Institute Baptist Health South Florida, lead author on, “Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update.” Thank you for being here today, Dr. Garje. Dr. Rohan Garje: Absolutely. Thank you so much for having me, Brittany. Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Garje, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to start on the content of this guideline, first, could you provide us an overview of the purpose of this guideline update? Dr. Rohan Garje: Sure. So ASCO has guidelines for prostate cancer and the specific guideline which we have updated for metastatic castrate-resistant prostate cancer was originally published in 2014. It's almost a decade. It's been a long time due for an update. Over the last decade, we have seen a lot of advances in the treatment of prostate cancer, specifically with regards to genomic testing, newer imaging modalities, and also the treatment landscape. Now we have newer options based on genomic targets such as PARP inhibitors, we have radiopharmaceuticals, a newer variant of chemotherapy, and also some specific indications for immunotherapy which were not addressed previously. Because all these advances have been new, it was really important for us to make an update. In 2022, we did make a rapid update with lutetium-177, but these additional changes which we have seen made it an appropriate time frame for us to proceed with a newer guideline. Brittany Harvey: Absolutely. It's great to hear about all these advances in the field to provide new options. So I'd like to next review the key recommendations from this guideline. So let's start with the overarching principles of practice that the panel outlined. What are these key principles? Dr. Rohan Garje: As a group, all the panel members came up with some ground rules: What are necessary for all our patients who are being treated for metastatic CRPC? First, the founding aspect was a definition for what is metastatic CRPC. So we defined metastatic CRPC as castrate level of testosterone with evidence of either new or progressive metastatic disease on radiological assessments or patients who have two consecutive rising PSAs in the setting of existing metastatic disease. We also emphasized on the need for germline and somatic testing for patients with metastatic prostate cancer at an earliest available opportunity because it is critical to select appropriate treatment and also right treatment for patients at the right time. And we actually have a concurrent guideline which addresses what genes to be tested and the timing. The other principles are patients should continue to receive androgen deprivation therapy or undergo surgical castration to maintain castrate level of testosterone. Now the key aspect with these guidelines is personalizing treatment choices. As you can see the evolution of treatment options for prostate cancer, the drugs that were initially developed and approved for prostate cancer were primarily in castrate-resistant settings, but now most of these drugs are being utilized in castrate-sensitive. So, when these patients develop castration resistance, the challenges are there are no appropriate particular drug-specific guidelines they meet. So, it's very important for the clinicians to be aware of what treatments have been received so far prior to castration resistance so that they can tailor the treatment to patient specific situations. In addition, prior to choosing a therapy, it is important for the physicians to consider patient specific symptoms or signs, treatment-related toxicities, potential drug interactions, cost, and also access to the drugs. There may be multiple treatment options available for the patients, but for a patient specific scenario, there may be a drug that may be more promising than the others. So, it is important to tailor the drug choices based on patients' unique circumstances. The panel also recommends to early integrate palliative and supportive care teams for symptom management and also discuss goals of care with the patient as each patient may have unique needs and it's important for physicians to address those concerns upfront in the care. The panel also suggests patients to receive RANK ligand inhibitors such as denosumab or bisphosphonates such as zoledronic acid to maintain the bone strength to prevent skeletal-related events. Finally, I would like to also emphasize this point about the lack of randomized clinical trial data for optimal sequencing of therapies for patients with metastatic CRPC. As I previously alluded, we have taken into account all ongoing clinical trials, prior published data, and came up with a format of preferred drugs based on prior treatments and, I think, by following these several clinical principles which I just mentioned, we can optimally choose and utilize best treatments for patients with metastatic CRPC. Brittany Harvey: Absolutely. These principles that you just outlined are important for optimal patient care, and then I want to touch on one of those things. You talked importantly about the treatments received so far. So in the next set of recommendations, the role of systemic therapy was stratified by the prior therapy received in the castration-sensitive and non-metastatic castration-resistant setting. So starting with what does the panel recommend for patients who are previously treated with androgen deprivation therapy alone in these previous settings and whose disease has now progressed to metastatic castration-resistant prostate cancer? Dr. Rohan Garje: There are multiple treatment options based on prior treatment received. So for patients who received only ADT for their castration-sensitive disease, the panel strongly urges to get HRR testing to check for homologous recombinant repair related changes, specifically for BRCA1 and BRCA2 mutations, because we have three studies which have really shown significant clinical benefit for patients who have BRCA1 and BRCA2 mutations with drugs such as the combination of talazoparib and enzalutamide or olaparib with abiraterone or niraparib with abiraterone. Unless we test for those mutations, we'll not be able to give these agents upfront for the patients. In the HRR testing, if patients have HRR alterations but they are in genes which are non-BRCA, the guideline panel recommends to utilize talazoparib and enzalutamide based combination therapies. Now, if they don't have HRR alterations then there are multiple treatment choices available. It could either include androgen receptor pathway inhibitors such as abiraterone with prednisone. We could also consider docetaxel chemotherapy. The alternate choices for androgen receptor pathways include enzalutamide or the newer agents such as apalutamide and docetaxel. So, as you can see there are multiple options available, but the panel definitely emphasizes to test for HRR testing because this gives patients access to more precision therapies at this point. There may be various scenarios where a unique drug may be available for a specific patient situation. For example, patients who have very limited disease burden and may have one or two metastatic lesions, after a multidisciplinary discussion, targeted local therapies such as radiation or potentially surgery could also be offered. In select patients who have very indolent disease where they are castrate-resistant based on slow rising PSA, low-volume disease or asymptomatic disease can consider sipuleucel-T. And in patients who have bone-only metastatic disease, we could also consider radium-223, which is primarily now utilized for patients who have symptomatic bone disease. Brittany Harvey: Great. I appreciate you reviewing all those options and talking about how important it is to tailor treatment to the individual patient. So then the next category of patients, what is recommended for those who have been previously treated with ADT and an androgen receptor pathway inhibitor and whose disease has now progressed to metastatic castration-resistant prostate cancer? Dr. Rohan Garje: So for patients who received ADT along with an androgen receptor pathway inhibitor, which we consider would be a most common cohort because most patients now in castration-sensitive setting are receiving androgen receptor pathway inhibitor. It was different in the past where five or six years back ADT alone was the most common treatment, but fortunately, with enough awareness and education, treatment choices have improved. Patients are now receiving ADT and ARPI as the most common choice of drug. Once again, at this point the panel emphasizes to consider HRR testing in there is enough data for us to suggest that patients who have alterations in the HRR pathway definitely will benefit with the PARP inhibitor. You know the multiple options, but specifically we speak about olaparib. And then if they are HRR-negative, we prefer patients receive agents such as docetaxel or if they are intolerant to docetaxel, consider cabazitaxel chemotherapy, options such as radium-223, and if they have a specific scenario such as MSI-high or mismatch repair deficiency, pembrolizumab could also be considered. The panel also discussed about the role of a second ARPI agent. For example, if patients progressed on one androgen receptor pathway inhibitor, the second androgen receptor pathway inhibitor may not be effective and the panel suggests to utilize alternate options before considering androgen receptor pathway inhibitor. There may be specific scenarios where a second ARPI may be meaningful, specifically, if alternate choices are not feasible for the concern of side effects or toxicities or lack of access, then a potential ARPI could be considered after progression on ARPI, but the panel definitely encourages to utilize alternate options first. Brittany Harvey: Great. Thank you for outlining those options as well for those patients. So then the next category, what is recommended for patients who have been previously treated with ADT and docetaxel? Dr. Rohan Garje: For patients who received ADT and docetaxel and were never treated with androgen receptor pathway inhibitors, the panel again emphasizes on HRR testing. If they have BRCA1 and 2 mutations, the combination therapies of talazoparib with enzalutamide, olaparib with abiraterone, or niraparib with abiraterone are all good choices. If they don't have BRCA mutations but they have other HRR mutations, the panel suggests to potentially utilize talazoparib with enzalutamide. And if they do not have any HRR alterations, the options could include androgen receptor pathway inhibitors such as abiraterone or enzalutamide. I want to emphasize that these are preferred options, but not the only options. As you can see, there are multiple options available for a particular clinical situation - so the ability of the physicians to access particular combinations, the familiarity of those drugs or the patient's unique situation where they have other medications which can potentially interact with a choice of agents. So I think based on access, based on cost and patients' concurrent illness with potential drug interactions can make one particular combination of therapy better over the other options. Brittany Harvey: Absolutely. That's key to keep in mind that access, contraindications, and cost all play a role here. So then the next set of recommendations. What are the key recommendations for patients who have previously been treated with ADT, an androgen receptor pathway inhibitor, and docetaxel who now have mCRPC? Dr. Rohan Garje: Yes. In this group, the options remain, again, broad. We utilize PSMA imaging here specifically and if they are positive on PSMA imaging, lutetium-177 is a good option. If they do not have PSMA-positive disease on PSMA imaging but if they have HRR alterations, olaparib could be utilized. And if they are negative on PSA imaging, they don't have HRR alterations, then alternate options could include cabazitaxel, radium-223. And if they have MSI-high or deficiency in mismatch repair, pembrolizumab could be utilized in this setting. Brittany Harvey: Thank you for outlining those options as well. So then next the panel addressed treatment options for de novo or treatment emergent small cell neuroendocrine carcinoma of the prostate. What are those key recommendations? Dr. Rohan Garje: Yes. This is a very high unmet need group because there are limited clinical trials, especially prospective clinical trials addressing treatment options for this group. Most of our current guidelines are always an extrapolation from lung small cell cancer based guidelines, but the panel recommends to utilize cisplatin or carboplatin along with etoposide as a preferred choice for this group. Also, an alternate option of carboplatin along with cabazitaxel could be considered for this cohort. The panel also encourages participation in clinical trials. There are numerous trials ongoing now in smaller phase studies and I think it's important for patients to consider these trials as well, because this will give them access to newer agents with potential biological targets. In addition to these agents in specific scenarios or potentially case by case basis, because we don't have prospective data, so we have made it as a select case by case basis to consider adding immunotherapy along with platinum-based chemotherapy followed by maintenance immunotherapy, which is currently a standard of care in small cell lung cancer. But the data is so limited in prostate cancer, so the panel suggested that it has to be a case by case basis only. The alternate options also include lurbinectedin, topotecan, tarlatamab upon progression on platinum-based chemotherapy. Brittany Harvey: Yes. It's important to have these recommendations in these unique situations where there is really a lack of data. So then the final set of recommendations I'd like to cover, what does the panel recommend for how clinicians should assess for response while patients are on systemic therapy and what scans are recommended for this response assessment? Dr. Rohan Garje: Yes. Again, this is another strong emphasis of the panel for global assessment of the patients. Traditionally, patients and physicians per se are heavily reliant on PSA as an accurate marker for response. This is in fact true in earlier phases of prostate cancer either in castrate-sensitive setting or localized prostate cancer setting. But as patients evolve into castrate-resistant, we don't want to heavily rely on PSA alone as a marker of response. The panel suggests to incorporate clinical response, radiological response, and also include PSA as a component, but not just rely primarily on PSA. So the panel also suggests that patients should get a bone scan and a CT scan every three to six months while on treatment to assess for appropriate response or for progression. And now one key important aspect, we are all aware about the evolving role of PSMA-based imaging with several of these new agents that are currently available. We do acknowledge these scans definitely have an important role in the care for patients with metastatic prostate cancer. Currently, the utility is primarily to select patients for lutetium-based therapy and also in situations where the traditional scans such as technitium 99 bone scan or CT scan are equivocal, then a PSMA-based imaging can be helpful. Now we are also aware that there are newer studies coming up, prospective data coming up for the role of PSMA-based imaging for response assessment. We are hoping to update the guidelines if we get access to newer data, but currently we have not recommended the utility of PSMA-based imaging for response assessments. Brittany Harvey: Understood. And I appreciate you describing where there is data here and where there's a lack of data to currently recommend. And we'll look forward to future updates of this guideline. Coming back to – at the start you mentioned how much has changed since the last guideline update. So Dr. Garje, in your view, what is the importance of this update and how will it impact both clinicians and patients with metastatic castration-resistant prostate cancer? Dr. Rohan Garje: The updated guidelines are designed to have a significant impact on clinical practice and also patient outcomes by providing clinicians with a comprehensive evidence-based framework for managing patients with metastatic CRPC. And also, by using these guidelines can make informed decisions, can select therapies tailored to patients' unique genomic status, clinical situation, where they are in the course of the cancer based on what they received previously. Also utilizing these guidelines, we can potentially improve patient outcomes, improve survival, and importantly have efficient use of healthcare resources. Brittany Harvey: Absolutely. We're always looking for ways to improve patient outcomes and survival. I want to wrap us up by talking a little bit about the outstanding questions in this field. So earlier you had mentioned about prospective data to come about PSMA PET scans, but what other outstanding questions are there for patients with metastatic castration-resistant prostate cancer? And what evidence is the panel looking forward to for future updates? Dr. Rohan Garje: We do have now rapidly evolving data specifically about the utility of the radiopharmaceutical lutetium-177 prior to chemotherapy. We are hoping that with newer data we can make some changes to the guideline based on that. We are also looking at newer drugs that are coming up in the pipeline, for example, androgen receptor degraders. We are looking at data that might potentially help based on bispecific T-cell engagers and newer radiopharmaceuticals. So I think in the next few years, we will definitely update all the guidelines again. But this time we are trying to do it more proactively. We are following a newer model. We are calling it as ‘living guidelines' where we are actually utilizing week by week updates where we look at the literature and see if there is any potential practice impacting change or publication that comes up. And we are trying to incorporate those changes as soon as they are available. That way patients and practicing physicians can get the latest information available through the guidelines as well. Brittany Harvey: That's great to hear. Yes, we'll await this data that you mentioned to continuously update this guideline and continue to improve patient outcomes for the future. So Dr. Garje, I want to thank you so much for your time to update this guideline. It was certainly a large amount of recommendations, and thank you for your time today, too. Dr. Rohan Garje: Thank you so much for having me here. And it's always nice talking to you. Brittany Harvey: And finally, thank you to our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/genitourinary-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Thorin and Peter Dun are joined by veteran coach Dan Dan to discuss G2 struggling in LEC and their potential to miss MSI, what it takes to build a winning team culture in League of Legends esports, the success of the Madrid homestand for MKOI, Nisqy's strange performance, and more!

This episode of ASCP Esty Talk finds Ella and Maggie tackling a topic that's red hot—literally! Yep, we're talking about rosacea. With over 415 million people affected worldwide, this condition is more common than you might think. But here's the good news: New advancements in rosacea research and treatments are making waves! From groundbreaking skin care ingredients to FDA-approved medications, we're diving into the latest breakthroughs.  ASCP Esty Talk with Maggie Staszcuk and Ella Cressman Produced by Associated Skin Care Professionals (ASCP) for licensed estheticians, ASCP Esty Talk is a weekly podcast hosted by Maggie Staszcuk and Ella Cressman. We see your passion, innovation, and hard work and are here to support you by providing a platform for networking, advocacy, camaraderie, and education. We aim to inspire you to ask the right questions, find your motivation, and give you the courage to have the professional skin care career you desire. About Ella Cressman: Ella Cressman is a licensed esthetician, certified organic formulator, business owner, ingredient junkie and esthetic cheerleader! Ella enjoys empowering other estheticians and industry professionals to understand skin care from an ingredient standpoint and how that relates to the skin.   Connect with Ella Cressman:   LinkedIn: www.linkedin.com/in/ella-cressman-62aa46a    About Maggie Staszcuk: Maggie has been a licensed esthetician since 2006 and holds a bachelor's degree in business administration from Stephens College. She has worked in the spa and med-spa industry and served as an esthetics instructor and a director of education for one of the largest schools in Colorado before coming to ASCP as the Education Program Manager.     Connect with Maggie:    P 800.789.0411 EXT 1636   E MStaszcuk@ascpskincare.com or AMI@ascpskincare.com   About our Sponsors The popular and revolutionary LAMPROBE utilizes radio and high-frequency technology to treat a wide variety of Minor Skin Irregularities™ (MSI)—non-invasively—with instantaneous results. Common conditions treated by the LAMPROBE include: vascular MSI, such as cherry angiomas; dilated capillaries; sebaceous MSI, including cholesterol deposits and milia; and hyperkerantinized MSI, such as keratoses and skin tags.   The LAMPROBE uniquely assists modern, capable, and skilled skin care practitioners to do their work more effectively and with greater client and professional satisfaction. Setting standards in quality, education, and training, the LAMPROBE has become an essential tool enabling skin care practitioners around the world to offer new revenue-enhancing and highly in-demand services.   Website: www.lamprobe.com   Email: info@lamskin.com   Phone: 877-760-2722   Instagram: www.instagram.com/lamprobe   Facebook: www.facebook.com/theLAMPROBE    TiZO Mineral Sunscreens set the standard for aesthetic elegance with tinted and non-tinted formulas for use on virtually all skin types and tones. Our name reflects our commitment: TIZO = Titanium dioxide + Zinc Oxides. All TiZO products are reef-friendly and 100% free of chemical sunscreens, dyes, fragrances, gluten, phthalates, and parabens.  TiZO Photoceutical Skincare is the perfect partner to our sunscreens in the fight against photoaging. These silky, elegant products address tone, texture and hydration while helping to prevent further damage. From our flagship TiZO3 Primer/Sunscreen SPF 40 to our gentle Ultra Zinc formulations to our NEW Advanced Vitamin C+E Serum with Bakuchiol, TIZO has the ideal selection of products to Protect, Repair, and Revitalize skin.    Website: https://tizoskin.com/   Facebook: @tizoskin  Pinterest: @tizoskin  Instagram: @tizoskin  YouTube: @tizoskin     Massage Envy is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services. Founded in 2002, Massage Envy now has approximately 1,100 franchise locations in 49 states that have together delivered more than 200 million massages and skin care services. Website: www.massageenvy.com/careers/career-areas/esthetician  Facebook: @MassageEnvyCareers LinkedIn: @MassageEnvy   About Associated Skin Care Professionals (ASCP):   Associated Skin Care Professionals (ASCP) is the nation's largest association for skin care professionals and your ONLY all-inclusive source for professional liability insurance, education, community, and career support. For estheticians at every stage of the journey, ASCP is your essential partner. Get in touch with us today if you have any questions or would like to join and become an ASCP member.   Connect with ASCP:   Website: www.ascpskincare.com   Email: getconnected@ascpskincare.com   Phone: 800-789-0411   Facebook: www.facebook.com/ASCPskincare   Instagram: www.instagram.com/ascpskincare    

The importance of creating inclusive and sensory-safe environments in the spa industry is becoming increasingly recognized. In this episode of ASCP Esty Talk, Maggie and Ella welcome Genice Gonzales, licensed esthetician and owner of Amora J Studios, to discuss the unique challenges and opportunities for estheticians when working with Autistic clients and others with sensory processing disorders. Genice shares her expertise in developing specialized protocols and her commitment to making the spa experience more accessible to all abilities. ASCP Esty Talk with Maggie Staszcuk and Ella Cressman Produced by Associated Skin Care Professionals (ASCP) for licensed estheticians, ASCP Esty Talk is a weekly podcast hosted by Maggie Staszcuk and Ella Cressman. We see your passion, innovation, and hard work and are here to support you by providing a platform for networking, advocacy, camaraderie, and education. We aim to inspire you to ask the right questions, find your motivation, and give you the courage to have the professional skin care career you desire. About Ella Cressman: Ella Cressman is a licensed esthetician, certified organic formulator, business owner, ingredient junkie and esthetic cheerleader! Ella enjoys empowering other estheticians and industry professionals to understand skin care from an ingredient standpoint and how that relates to the skin.   Connect with Ella Cressman:   LinkedIn: www.linkedin.com/in/ella-cressman-62aa46a    About Maggie Staszcuk: Maggie has been a licensed esthetician since 2006 and holds a bachelor's degree in business administration from Stephens College. She has worked in the spa and med-spa industry and served as an esthetics instructor and a director of education for one of the largest schools in Colorado before coming to ASCP as the Education Program Manager.     Connect with Maggie:    P 800.789.0411 EXT 1636   E MStaszcuk@ascpskincare.com or AMI@ascpskincare.com   About our Sponsors The popular and revolutionary LAMPROBE utilizes radio and high-frequency technology to treat a wide variety of Minor Skin Irregularities™ (MSI)—non-invasively—with instantaneous results. Common conditions treated by the LAMPROBE include: vascular MSI, such as cherry angiomas; dilated capillaries; sebaceous MSI, including cholesterol deposits and milia; and hyperkerantinized MSI, such as keratoses and skin tags.   The LAMPROBE uniquely assists modern, capable, and skilled skin care practitioners to do their work more effectively and with greater client and professional satisfaction. Setting standards in quality, education, and training, the LAMPROBE has become an essential tool enabling skin care practitioners around the world to offer new revenue-enhancing and highly in-demand services.   Website: www.lamprobe.com   Email: info@lamskin.com   Phone: 877-760-2722   Instagram: www.instagram.com/lamprobe   Facebook: www.facebook.com/theLAMPROBE     TiZO Mineral Sunscreens set the standard for aesthetic elegance with tinted and non-tinted formulas for use on virtually all skin types and tones. Our name reflects our commitment: TIZO = Titanium dioxide + Zinc Oxides. All TiZO products are reef-friendly and 100% free of chemical sunscreens, dyes, fragrances, gluten, phthalates, and parabens.  TiZO Photoceutical Skincare is the perfect partner to our sunscreens in the fight against photoaging. These silky, elegant products address tone, texture and hydration while helping to prevent further damage. From our flagship TiZO3 Primer/Sunscreen SPF 40 to our gentle Ultra Zinc formulations to our NEW Advanced Vitamin C+E Serum with Bakuchiol, TIZO has the ideal selection of products to Protect, Repair, and Revitalize skin.    Website: https://tizoskin.com/  Facebook: @tizoskin  Pinterest: @tizoskin  Instagram: @tizoskin  YouTube: @tizoskin     Massage Envy is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services. Founded in 2002, Massage Envy now has approximately 1,100 franchise locations in 49 states that have together delivered more than 200 million massages and skin care services. Website: www.massageenvy.com/careers/career-areas/esthetician  Facebook: @MassageEnvyCareers LinkedIn: @MassageEnvy   About Associated Skin Care Professionals (ASCP):   Associated Skin Care Professionals (ASCP) is the nation's largest association for skin care professionals and your ONLY all-inclusive source for professional liability insurance, education, community, and career support. For estheticians at every stage of the journey, ASCP is your essential partner. Get in touch with us today if you have any questions or would like to join and become an ASCP member.   Connect with ASCP:   Website: www.ascpskincare.com   Email: getconnected@ascpskincare.com   Phone: 800-789-0411   Facebook: www.facebook.com/ASCPskincare   Instagram: www.instagram.com/ascpskincare